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ABSTRACT 
Lipoate is an essential cofactor of several proteins involved in cellular 
energy homeostasis and catabolism. Lipoate metabolism has been linked to 
pathogenesis in some microbial species, but its role in Staphylococcus aureus 
infections had not been explored. In this thesis, we tested the hypothesis that 
lipoate acquisition mechanisms promote S. aureus infectivity. We used a 
bacterial genetics approach to elucidate the biological function of the S. aureus 
genes involved in lipoate metabolism. Our findings allowed us to propose a 
model for lipoic acid de novo biosynthesis and salvage pathways in S. aureus. 
Moreover, we detail hitherto undescribed genetic arrangements of lipoate de 
novo biosynthesis and salvage genes in the S. aureus genome, which suggest a 
potential role for lipoate acquisition mechanisms in metabolic regulation and 
oxidative stress defense. Also, we have identified critical requirements for gene 
products involved in lipoate metabolism in murine sepsis. Our data indicate that 
S. aureus is capable of using bacterial and host-derived lipoate during infection in 
a tissue-specific manner, thereby promoting survival in diverse nutrient-restricted 
environments. Overall, our findings suggest that the S. aureus lipoate de novo 
biosynthesis and salvage pathways offer potential for the development of novel 
therapeutics that target key metabolic programs in S. aureus.  
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CHAPTER ONE  
LITERATURE REVIEW 
Introduction  
 Staphylococcus aureus is a commensal bacterium that can be found 
colonizing the skin in humans. About a fifth of the human population are 
permanently colonized with S. aureus and almost of 60% of humans are 
occasional carriers (1-3). S. aureus is also a prominent pathogen capable of 
invading several organs and tissues causing mild to severe, or even fatal 
infections (2-4). Special concern has been raised in society over the increasing 
number of patients infected with hypervirulent or antimicrobial-resistant S. aureus 
strains, acquired by both immunocompromised patients at health-care facilities 
and otherwise healthy individuals from community environments (5-8). 
   S. aureus has developed sophisticated strategies to survive in different 
mammalian tissues, both as a commensal and as a pathogen. Upon infection, it 
evades the host immune responses by secreting numerous virulence factors, 
such as pore-forming toxins and proteases (3, 4). Moreover, this species readily 
adapts to nutrient restriction to survive within the host; iron acquisition 
mechanisms are a clear example of the remarkable ability of S. aureus to hunt for 
nutrients (9, 10). 
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 Lipoate is an essential cofactor in central metabolism in bacteria since it 
enables the function of several proteins that lead to the production of cellular 
energy and vital metabolites, such as amino acids and fatty acids (11, 12). 
Interestingly, lipoate acquisition pathways have been linked to pathogenesis in 
several bacterial and malarial species (13-18). For example, Listeria 
monocytogenes, which is a Gram-positive pathogen that belongs to the same 
taxonomic phylum as S. aureus, requires lipoate salvage to infect the host, 
demonstrating that the mechanism for incorporating this cofactor could promote 
pathogenesis in a wide range of bacteria (16, 19). 
 A deep understanding of the elements that promote S. aureus fitness and 
prevalence during infection is a matter of paramount importance for the design of 
new therapeutics against this pathogen. Lipoate metabolism in S. aureus is 
poorly understood and the role of lipoate acquisition during infection is currently 
unknown (16). Therefore, investigating S. aureus lipoate metabolism and its role 
in pathogenesis could reveal novel targets for developing antimicrobial agents 
against this major pathogen.  
Staphylococcus aureus 
S. aureus is a major human pathogen 
 Skin and soft tissue infections such as impetigo, folliculitis and cellulitis are 
amongst the most common diseases caused by S. aureus (5, 7, 8, 20). This 
pathogen can also cause respiratory diseases such as pneumonia and can 
induce sepsis upon spread into the bloodstream (3, 21). Furthermore, S. aureus 
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is the leading cause of infectious endocarditis in the United States and is often 
associated with osteomyelitis in young children (22-25). Mortality and morbidity 
due to staphylococcal infections constitute a significant economic burden for 
society (5, 26, 27). 
 A variety of factors can increase the risk of infection in patients. These 
include the use of foreign bodies such as catheters or prostheses, the presence 
of underlying health conditions, as well as current or recent hospitalization. In 
addition, treatment of S. aureus-derived diseases constitutes a current challenge 
in public health due to the increasing antimicrobial resistant strains found in the 
clinic (5, 8, 22, 27, 28). 
 According to the World Health Organization’s First Global Report on 
Antibiotic Resistance (28), people infected with MRSA (methicillin-resistant S. 
aureus) are estimated to be 64% more likely to die than those infected with non-
resistant strains. A clear understanding of S. aureus pathogenesis could have a 
significant socio-economic impact on the prevention and treatment of both 
community-acquired and hospital-acquired infections (5, 7, 8, 29). 
Numerous virulence factors contribute to S. aureus pathogenicity 
 The ability to infect and survive in a broad spectrum of host tissues makes 
S. aureus a major pathogen. In order to cause disease, the bacterium has to 
colonize the host while simultaneously evading and/or suppressing host immune 
responses (6, 30). To counter these defense mechanisms and succeed at 
infecting the host, S. aureus produces numerous virulence factors (1, 3, 6, 31).  
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 Among the arsenal of S. aureus virulence factors are several key surface 
proteins (6, 32). These cell wall-anchored (CWA) proteins are attached to 
peptidoglycan and mediate processes such as attachment to host cells, 
disruption of immune responses or stimulation of biofilm formation (6, 33). For 
example, the protein Clumping factor B is capable of binding fibrinogen and 
molecules expressed by squamous cells, thus promoting attachment to the skin 
surface (3). Another group of S. aureus CWA proteins, the iron-regulated surface 
determinant (Isd) proteins, facilitate iron binding and uptake, and support survival 
in iron-limiting environments including the skin and mucosa (31, 34). Expression 
of several CWA proteins depends on growth conditions and S. aureus nutritional 
status, highlighting their role in promoting adaptation to fluctuations in 
environmental conditions (1, 3, 32). Another major CWA S. aureus virulence 
factor is the deeply studied Protein A, which sequesters antibodies by binding 
IgG molecules by the Fc region (6, 31, 35). This prevents proper recognition by 
Fc receptors on phagocytic leukocytes interfering with phagocytosis and 
activation of the complement cascade. 
 As highlighted by the function of the CWA Protein A, S. aureus is capable 
of producing a wide variety of both cell wall linked and secreted factors that 
protect against major host immune defenses including, but not limited to, 
phagocytosis and complement activation. During infection with S. aureus, one of 
the most important mechanisms used to combat the pathogen is 
opsonophagocytosis and subsequent induction of the respiratory burst (30, 31, 
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36). This process is initiated by migration of neutrophils to the site of infection, an 
event that is mediated by a gradient of diffusible peptides derived from the 
pathogen (i.e. N-formyl peptides) and the host, (i.e. complement degradation 
products). Upon reaching the site of infection, neutrophils pass through the blood 
vessel endothelium and migrate into the tissue. S. aureus interferes with these 
processes by secreting inhibitory molecules that can block neutrophil adhesion 
and migration (30, 31, 36). For example, S. aureus produces the staphylococcal 
superantigen-like proteins -5 and 11, which compete with neutrophil cell 
receptors and decrease neutrophil binding and rolling through the endothelium 
(3, 37). Additionally, S. aureus is capable of inhibiting neutrophil migration to 
infected tissues by secreting small proteins such as CHIPS, chemotaxis inhibitory 
protein of staphylococci, and SCIN, Staphylococcal complement inhibitor, which 
binds receptors on the membrane of neutrophils, preventing the process of 
chemotaxis and allowing the bacterium to evade phagocytosis (38-40). 
 Although inhibiting phagocyte recruitment and complement activation are 
key virulence strategies, S. aureus also employs other methods to evade the 
respiratory burst initiated after phagocytosis. For example, S. aureus can detoxify 
reactive oxygen species by producing enzymes such as catalase, superoxide 
dismutase and a variety of other proteins with antioxidant properties (1, 3, 6, 35). 
 Secreted toxins also play a major role in the pathogenesis of S. aureus. 
Most noteworthy are the myriad cytotoxic agents that can damage host cell 
membranes. The membrane damaging α-toxin, also known as Hla or alpha-
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hemolysin, is one of the most studied virulence factors in S. aureus (40, 41). The 
toxin binds to specific receptors on susceptible cells to induce lysis, releasing 
cytosolic content that trigger a potent inflammatory reaction. Another group of 
secreted proteins, named leukocidins, specifically target immune cells by forming 
pores after oligomerization on the cell surface. The leucocidins include HlgAB, 
HlgCB, LukAB/HG, LukMF, Panton-Valentine leucocidin (PVL), and LukED. This 
wealth of bicomponent pore-forming proteins leads to a broad spectrum of 
hemolytic, leukotoxic and dermonecrotic activities (23, 31, 42). Finally, phenol-
soluble modulins are a group of small amphipathic cytolytic peptides produced by 
S. aureus that can target white and red blood cells and promote inflammation in 
the host (2, 3, 31, 42). 
 S. aureus enhances its pathogenicity through its ability to recover 
essential nutrients from the site of infection. The scavenged compounds are then 
used for all sorts of biochemical processes, from DNA synthesis to the production 
of energy. Moreover, alterations in S. aureus nutrient-acquisition mechanisms 
have been shown to affect its virulence (4, 10). The acquisition of transition 
metals is a great example that demonstrates how S. aureus competes with the 
host for essential nutrients (43). Mammalian cells have evolved mechanisms that 
restrict iron availability, such as the intracellular location of iron and its 
sequestration within iron-binding proteins, such as transferin, lactoferrin or 
hemoproteins (34, 44). These strategies limit the proliferation of pathogens in a 
defense process known as “nutritional immunity” (45). To circumvent this 
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nutritional restriction, S. aureus has evolved mechanisms to release and 
incorporate iron from host deposits, mainly from heme, which is the primary iron 
reservoir in mammals. Proteins from the heme uptake systems extract 
sequestered iron and the iron-chelators staphyloferrin A and B and aurochelin 
facilitate the passage of this essential nutrient to the bacterial cytosol. These iron-
dependent siderophores are upregulated in iron-deprived conditions (34, 44). 
Interestingly, heme uptake systems, such as the Isd system, have been shown to 
be essential for S. aureus pathogenesis by promoting trace metal acquisition that 
leads to bacterial proliferation and persistence in the host (3, 10, 34, 43, 46). 
A note on antimicrobial resistance  
 While the production of virulence factors is critical to S. aureus 
pathogenesis, additional acquisition of a broad range of antibiotic resistance 
genes has further augmented S. aureus pathogenicity and adverse outcomes 
associated with failed treatment. Infections with antibiotic resistant bacterial 
decrease the available tools to treat diseases and increase the patient's risk of 
suffering from more severe complications. The prevalence and widespread 
dissemination of antibiotic resistance genes has become a serious problem and a 
major public health crisis. Meanwhile, very few novel therapeutic strategies are 
being developed.  
 The extensive use of antibiotics both in the community, the clinic and in 
the food industry has contributed to the selection of antimicrobial resistance 
determinants in bacteria and promoted the emergence of pan-resistant species 
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(47). Despite the role of the selective pressure derived from antibiotic utilization, 
antimicrobial resistance in bacteria is a phenomenon rooted in complex genetic 
mechanisms, including chromosomal alterations and trade of genetic information 
among species (47, 48). (49). 
 For S. aureus, resistance to antimicrobials resides in its high adaptability 
and mutability, which facilitate gene variations and the rapid incorporation of 
extrachromosomal DNA (1, 5, 26). As a consequence of its multi-drug resistant 
phenotype and its incidence worldwide, methicillin resistant S. aureus (MRSA) 
has been widely studied (8, 20). Methicillin resistance in S. aureus occurred after 
acquisition of a mobile genetic element known as the staphylococcal cassette 
chromosome mec (SCCmec); SCCmec contains the mecA gene, which confers 
resistance to penicillin drugs and β-lactam antibiotics, and it may carry additional 
genes involved in resistance to other classes of antimicrobials and toxins, such 
as the Panton-Valentine leucocidin (8, 50). 
 The rise of antibiotic resistance has not been restricted to methicillin since 
a few S. aureus strains have begun to show reduced susceptibility to 
antimicrobials commonly used to fight MRSA and infections caused by other 
pathogens. Researchers hypothesize that intense use of the antibiotic 
vancomycin as the therapeutic approach infections constituted a strong selective 
pressure that fostered the acquisition of the vanA operon from vancomycin-
resistant enterococci (8, 47, 51). Additionally, resistance to non-β-lactam 
antibiotics such as clindamycin has been detected in MRSA isolates from the 
9 
	  
community. This antibiotic resistance has been associated with the presence of 
the pUSA03 plasmid containing the resistance genes ermA and ermC (5, 8) 
 The growing number of infections caused by multi-drug resistant and 
highly virulent S. aureus strains isolated from community settings is a major 
public health concern. Thus, further research on potential antimicrobial targets 
and novel therapeutic approaches is required to reverse the increasing trend on 
multi-drug resistance in S. aureus.  
Final considerations 
S. aureus is a fascinating and exceptionally successful pathogen. The 
combined action of immunoevasion, immunosuppression, and nutrient 
scavenging activities, in addition to its rapid acquisition of antibiotic resistance, 
allow it to thrive in disadvantageous circumstances. In light of the information 
provided in the literature, we can surmise that the outcome of a staphylococcal 
infection is the result of a fine balance between the host immune responses and 
the ability of the pathogen to subvert those defensive actions. On one side of the 
spectrum, S. aureus infections can remain asymptomatic or localized due to 
effective host defenses; on the other side lays the risk of bacterial dissemination 
and disease due to bacterial counter-measures.  
 An increasing number of MRSA strains have begun to display complete or 
partial resistance to previously effective drugs, reducing the spectra of available 
effective antimicrobial drugs against this pathogen (5, 8, 50). The increased 
frequency of infections caused by hyper virulent strains that show resistance to 
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multiple antibiotics emphasizes the urgency of comprehensive studies on the 
causes, severity and treatment of S. aureus infections. 
Lipoate metabolism 
Lipoate is required for metabolism and redox homeostasis  
 Lipoate is the deprotonated form of lipoic acid (Figure 1) (16). It is highly 
conserved among species of different domains of life and acts as an essential 
organosulfur cofactor in key multienzyme complexes that are involved in 
oxidative and one-carbon metabolism (11). Lipoate itself and lipoylated 
complexes are well conserved in nature, yet an important versatility exists among 
organisms regarding their requirements for lipoate and its acquisition (11, 16).  
 Five multienzyme complexes depend on lipoate to function and these 
have been extensively described in the literature: pyruvate dehydrogenase 
complex (PDH); 2-Oxoglutarate dehydrogenase (OGDH); branched-chain 2-
Oxoacid dehydrogenase (BCODH); the glycine cleavage system (GCS) and 
acetoin dehydrogenase complex (AoDH). Of note, all except one are encoded in 
S. aureus genome; the AoDH is not synthesized or required for its metabolic 
functions (11, 16).  
 The three 2- oxoacid dehydrogenases are composed of multiple copies of 
three enzymatic subunits, E1, E2 and E3. The core of the complex contains the 
E2 subunit bearing the lipoate molecule covalently attached to a well-conserved 
lysine through an amide bond (Figure 1B) (16). Pyruvate dehydrogenase (PDH) 
converts pyruvate to acetyl coenzyme A; 2-Oxoglutarate dehydrogenase (OGDH) 
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is involved in the transformation of α-ketoglutarate into succinyl-CoA and the 
branched-chain 2-Oxoacid dehydrogenase (BCODH) participates in the initial 
steps of branched chain fatty acid synthesis (11, 16). The glycine cleavage 
system (GCS) catalyzes the reversible decarboxylation of glycine and shows 
differences in both sequence and structure compared to the 2- oxoacid 
dehydrogenases. The GCS also contains a lipoate molecule attached to a 
conserved lysine, but it is bound to the H subunit of this system (GcvH) (6). An 
additional gene product related to the GCS has been found within the SirtM 
operon of S. aureus, which encodes an ADP-ribosyltransferase and a non-
canonical form of the Glycine cleavage complex H (gcvH-L) that appears to be 
upregulated under conditions of redox stress (52, 53). Finally, the acetoin 
dehydrogenase complex (AoDH), which is not present in S. aureus, also has 
three catalytic subunits and is functionally related to PDH, but it does not 
catalyze the oxidative decarboxylation of branched-chain 2-Oxoacids (16).  
Despite their structural and functional differences, PDH, OGDH, BCODH 
and GCS share an E3 subunit, which is responsible for recycling the disulfide 
bond for a new catalytic cycle (11, 16). In these multienzyme complexes, the 
lipoate molecule is responsible for binding substrates through its thioester bond, 
where it tunnels those substrates between the active sites of the different 
subunits (11). In addition to its role in catalysis, the disulfide bond formed by the 
thiol groups is thought to be involved  in redox reactions, conferring an important 




















Figure 1: Structure and function of the cofactor lipoate 
A. The biologically active form of lipoic acid, lipoate. B. Reactions catalyzed by 2-Oxoacid 
dehydrogenase complexes. First, the E1 subunit decarboxylates the 2- oxoacid substrate, 
subsequently, the lipoyl cofactor on the E2 subunit transfers the acyl group to coenzyme A (CoA). 
At the end of the cycle, lipoate is regenerated after reduction of NAD+. Reprinted with permission 





Lipoate can be scavenged or generated endogenously 
 Lipoylation is the posttranslational modification of proteins with lipoate, 
and it can occur by two known mechanisms: via lipoate biosynthesis or through 
lipoate scavenging from environmental sources (11). For those organisms that 
can generate lipoate, de novo biosynthesis is catalyzed by the action of a lipoate 
synthetase LipA, which uses octanoate, a molecule derived from fatty acid 
metabolism, as a precursor (16, 54, 55). Lipoate scavenging, instead, involves 
the acquisition of this cofactor from the environment and the direct ligation onto 
proteins. This process is referred to as the salvage pathway and is catalyzed by 
lipoate ligases (11, 15, 56). 
 Lipoate de novo biosynthesis occurs in two sequential steps, the transfer 
of octanoate from an acyl carrier protein (ACP) to a protein subunit (generally a 
member of one of the metabolic complexes described above), followed by the 
insertion of two sulfur atoms into the octanoate backbone (11). The initial ligation 
of octanoate to ACP depends on the enzymatic activity of the type II fatty acid 
synthetase; the direct transfer of octanoate from ACP to a conserved lysine of 
the target protein is catalyzed by an octanoyl transferase, which has been well 
characterized in numerous species (11, 54, 57). Finally, LipA catalyzes the 
irreversible conversion of the octanoyl group to a lipoate molecule by generating 
a disulfide bond (11, 57).  
 Lipoate biosynthesis can be bypassed by the action of lipoate ligases, 
which catalyze the insertion of free lipoate through generation of an amide bond 
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directly to the E2/H subunit of the enzyme complexes (11). Since free lipoate is 
rarely found to the environment due to its exclusive linkage to the protein 
subunits of PDH, OGDH, BCODH, AoDH complexes, as well as GCS, free 
lipoate has to first be made available by enzymes capable of breaking the lipoyl-
protein amide bond (11, 16). Free lipoate in vivo is believed to come mostly from 
the gastrointestinal tract, where lipoate is released from lipoyl-proteins by the 
action of an intestinal amidase. For bacterial pathogens, lipoate most likely 
comes from damaged tissue, though it is not known whether or not all or some 
bacterial species encode an analogous amidase or similar enzyme that releases 
lipoate from source lipoyl-peptides (16). Of note, some ligases are also involved 
in the salvage of octanoate, which means that they can incorporate octanoate 
into target proteins, bypassing the action of the octanoyl transferase; yet, the use 
of octanoate as an exogenous source necessitates that the bacterium have a 
functional lipoate synthetase to generate lipoic acid (11, 16, 54). 
 Escherichia coli, Bacillus subtilis, and Listeria monocytogenes are three 
bacteria whose lipoate biosynthesis and salvage pathways are well 
characterized. In E. coli, de novo lipoate biosynthesis occurs after the sequential 
action of an octanoyl transferase, LipB, and a lipoate synthetase, LipA, as 
described above. The lipoate ligase, LplA, is capable of using both free lipoate 
and octanoate to bypass this de novo biosynthesis pathway (58).  
 Figure 2 depicts B. subtilis pathways for protein lipoylation. Unlike E. coli, 
the B. subtilis lipoate biosynthesis and salvage pathway requires four enzymes 
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and is now considered the model pathway of bacterial lipoylation in Gram-
positive bacteria (11, 54, 59). Despite having a low degree of amino acid 
sequence homology, B. subtilis LipM catalyzes the same reaction as E. coli LipB; 
both are octanoyl transferases that remove an octanoate group exclusively from 
an octanoyl-ACP and neither enzyme has ligase activity. In B. subtilis the 
octanoyl group is transferred from the ACP to the H subunit of the GCS. This 
observation is consistent with the hypothesis that GcvH is the first protein to be 
lipoylated through the de novo biosynthesis in other microorganisms, such as 
Plasmodium facilparum and Toxoplasma gondii (14, 59, 60). In addition to LipA 
and LipM, the B. subtilis genome encodes a lipoate ligase, LplJ, and the 
amidotransferase, LipL, capable of transferring both lipoate and octanoate (11, 
59).  
 The food-borne human pathogen L. monocytogenes is a lipoate 
auxotroph; it does not have a LipM or LipA homologs, thus, it has no means to 
generate lipoate endogenously (16, 61). Nevertheless, this Gram-positive 
bacterium has retained an amidotransferase enzyme, LipL and has two lipoate 
ligases, LplA1 and LplA2 (16, 61). Remarkably, whole cell extracts of L. 
monocytogenes have shown to have amidase activity, which facilitates the 
release of lipoate from mammalian tissues followed by incorporation into E2 and 








Figure 2: B. subtilis lipoylation mechanisms 
This is the model lipoate biosynthesis pathway for B. subtilis (modified from Spalding et al. 
Reprinted with permission from Spalding and Prigge (Figure 16 - Appendix I). Lipoate de novo 
biosynthesis initiates with the transfer of an octanoyl group from an acyl carrier protein (ACP) to a 
metabolic complex protein subunit (Octanoyl-E2) by the octanoyl transferase LipM. Subsequently, 
the lipoate synthetase LipA catalyzes the irreversible conversion of octanoate to lipoate (Lipoyl-
E2). LipL is involved in transferring lipoate groups among different subunits of the lipoylated 
enzyme complexes (Lipoyl-P2). Through the lipoate salvage pathway free lipoate is directly 
bound to the protein subunit through the action of the lipoate ligase, LplJ (16, 54, 59). 
 
Mechanisms of lipoate acquisition vary among microbial species 
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within the same phylum. In 2010, M.D. Spalding and S.T. Prigge surveyed the 
literature on lipoic acid metabolism in bacterial, fungal, and protozoan 
microorganisms and described the remarkable degree of diversity that exists 
among microbial species (16). For example, the review indicates that some 
species lack the enzymatic machinery to produce lipoate endogenously, while 
others cannot scavenge lipoate or do not require lipoate to support survival at all. 
Furthermore, not all species express the five known lipoylated enzyme 
complexes, highlighting the diversity of lipoate acquisition and its metabolic 
enzyme complexes in nature (11, 16, 61).  
  A comparison between Pseudomonas aeruginosa and Helicobacter pylori 
highlights the diversity of lipoylation strategies found in Gram-negative bacteria. 
H. pylori does not require lipoate enzymes to sustain growth. The bacterium 
maintains an active TCA cycle by replacing the requirement of lipoic acid-
containing enzymes, KDH and PDH, with the alternate 2-Oxoglutarate 
oxidoreductase (KOR) and the pyruvate:flavodoxin oxidoreductase (POR) (16). 
In contrast, P. aeruginosa uses both the salvage and the biosynthesis pathway to 
incorporate lipoate to five lipoylated enzyme complexes required for metabolic 
efficiency (16). 
 Mycobacterium tuberculosis, Mycobacterium leprae and Corynebacterium 
diphtheriae are three species of Actinobacteria that appear to depend exclusively 
on the endogenous synthesis of lipoate, as they do not encode lipoate ligases. 
These species have a lipoate metabolic pathway that resembles that of Gram-
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negative bacteria, although they lack of a KDH complex, whose function is 
replaced by a 2-Oxoglutarate decarboxylase (16).  
Gram-positive bacteria belonging to the phyla Firmicutes display additional 
diversity in their lipoate utilization strategies. Some Clostridia species are lipoate 
auxotrophs and encode a single lipoate ligase, while the major pathogenic 
species within the order Bacillales can encode multiple lipoate ligases, a lipoate 
synthetase, or both (16). For example, L. monocytogenes is a lipoate auxotroph 
that encodes two lipoate ligases, LplA1 and LplA2 (61). Interestingly, these 
lipoate ligases use different lipoylated substrates to replicate and have discrete 
biological roles in vivo and in vitro (15, 19). B. subtilis encodes one lipoate ligase, 
LplJ and has a complete set of enzymes dedicated to de novo biosynthesis 
pathway (54, 59). The lipoic acid biosynthesis and salvage pathways of S. 
aureus are currently unknown, but this species seems to encode a lipoate 
synthetase and several lipoate ligases (16). Additionally, L. monocytogenes, B. 
subtilis and S. aureus have different sets of lipoylated enzyme complexes; B. 
subtilis codes for PDH, OGDH, BCODH, GCS and AoDH; S. aureus lacks AoDH 
but encodes two GcvH proteins and L. monocytogenes lacks both KDH and 
AoDH (16). 
 Protein lipoylation in yeasts is restricted to the mitochondria. These 
microorganisms encode only three lipoylated enzyme complexes, PDH, KDH and 
GCS and three enzymes involved in lipoate metabolism, Lip2, Lip3 and Lip5. 
Saccharomyces cerevisiae and Candida albicans have the functional enzymatic 
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machineries to generate lipoate endogenously (Lip2 and Lip3 are E. coli LipB 
and LipA orthologs, respectively), but cannot scavenge lipoate despite encoding 
a lipoate synthetase (Lip3). Interestingly, Lip3 is an amidotransferase involved in 
transporting lipoyl groups from GCS to PDH and KDH. Thus, Lip2 and Lip5 are 
required to lipoylate GCS and Lip3 confers the ability to lipoylate the additional 
enzyme complexes found in the mitochondria (16). 
 In the pathogenic protozoans Plasmodium falciparum and Toxoplasma 
gondii, lipoate is attached to the E2 subunits of PDH, OGDH, BCODH and the H 
subunit of GCS, resembling the enzyme complexes found in Gram-positive 
bacteria (13, 14, 18). Interestingly, the lipoylated complexes have different 
subcellular location inside these parasites; PDH is located in the apicoplast and 
GCS and BCODH are present in the mitochondrion (16, 60). Furthermore, 
protein lipoylation differs in each organelle, with lipoate biosynthesis occurring in 
the apicoplast and lipoate salvage occurring in the mitochondrion (17, 62). In 
addition, malarial parasites encode LipA and LipB orthologs and two lipoate 
ligases (14). As in L. monocytogenes, P. falciparum lipoate ligases have 
substrate specificity; lipL1 preferentially lipoylates OGDH and PflipL2 catalyzes 
the lipoylation of PDH (16).  
 In summary, lipoate is a conserved molecule that permits the function of 
well-conserved enzyme complexes. Importantly, microbial species display a 
remarkable diversity regarding lipoylation strategies, highlighting the role of 
lipoate metabolism in adaptation to a variety of environmental niches. 
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To date, the S. aureus lipoate biosynthesis and salvage pathways have not been 
elucidated. Sequence alignment analyses suggest that this pathogen encodes a 
lipoate synthetase ortholog and several lipoate ligases, but no octanoyl 
transferase seems to be present in its genome. However, attempts to predict 
functions based exclusively on amino acid homology in other species have led to 
mistaken annotations and thus, the enzymatic activity of these putative lipoate 
ligases deserves further investigation (6, 15). 
Lipoate biosynthesis and salvage in microbial pathogenesis 
 Intuitively, the fundamental role of lipoate in catalysis and redox reactions 
might have important implications for microbial pathogens, which often face 
nutritional restrictions and reactive oxygen intermediates during host infection. 
When considering microbial pathogenesis, the mechanisms of lipoate acquisition 
have been found to promote survival and adaptation in different pathogens, from 
bacteria to parasites and fungal species (11, 16). For example, it has been 
shown that PDH mediates expression of T3SS in P. aeruginosa by stabilizing the 
bacterial metabolic status through the production of acetyl-CoA (63). Additionally, 
it has been established that the disruption of a lipoylated complex in M. 
tuberculosis leads to increased susceptibility to macrophage killing and reduces 
its pathogenicity (64). Finally, evidence suggests that lipoate scavenging in the 
malarial parasite P. falciparum is required to infect the host (13, 16-18, 62).  
 The distinct roles that L. monocytogenes lipoate ligases, LplA1 and LplA2, 
have in vivo and in vitro constitute a remarkable example of adaptation to nutrient 
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deprivation during infection (61). One of its lipoate ligases, LplA1 has evolved to 
function during infection, sequestering lipoate from the host. Interestingly, this 
enzyme is dispensable in culture media (15, 61). Moreover, LplA1 and LplA2 are 
capable of using alternative sources of lipoate, an effect that is facilitated by a yet 
to be identified amidase present in whole cell lysates, which allows this pathogen 
to take better advantage of restricted nutrients that are not immediately 
bioavailable within the host (15, 59). 
 L. monocytogenes lipoate metabolism has also been topic of interest in 
the context of protein secretion since the E2 PDH and GcvH subunits have been 
found associated with the external bacterial surface. It is thought that these 
proteins are secreted by an accessory secretion system in L. monocytogenes, 
SecA2, which is required for virulence (16, 65). Although is currently unknown if 
these E2 and H subunits are being actively secreted to support pathogenesis, 
this raises the possibility that lipoylated proteins have a secondary function, 
dissimilar from its original metabolic role, in what is referred to as a moonlighting 
capacity (16, 65). 
 Having alternative lipoate acquisition mechanisms that enable lipoate 
scavenging from resource-deprived contexts constitutes an important asset for 
bacterial pathogens, beyond that of conferring metabolic adaptability. As stated 
above, lipoate can confer antioxidant protection by quenching free radicals that 
can ultimately kill bacterial cells. It does so by forming a redox couple with its 
reduced form, the molecule dihydrolipoate. The dihydrolipoate-lipoate pair is 
22 
	  
capable of neutralizing superoxide radicals, the hydroxyl radical and hydrogen 
peroxide, as well as interacting with other antioxidants present in the cell 
membrane and the cytosol (6, 17, 18). 
Concluding remarks 
 As described above, S. aureus is a versatile bacterium that produces 
myriad virulence factors in order to support colonization, tissue damage and 
dissemination in the host. Moreover, S. aureus has an astonishing capacity to 
adapt to different nutritional conditions as shown by its ability to scavenge 
essential nutrients, such as iron (43, 44). Unraveling the existing mechanisms 
behind S. aureus infection strategies is of paramount importance to develop new 
therapeutic strategies with the potential to reduce the morbidity and mortality 
associated with clinical disease. This thesis aims to study the role of one 
essential nutrient, lipoate, to determine its contribution to S. aureus fitness and 
pathogenesis.  
 The intersection of lipoate metabolism and virulence was first delineated 
by the discoveries that linked lipoate acquisition to bacterial and malarial 
pathogenesis, as shown for L. monocytogenes, T. gondii and P. falciparum (14, 
15, 19, 62). The association of lipoate acquisition with microbial infection might 
be based on the fundamental role that this cofactor has in aerobic metabolism 
and redox homeostasis or may extend to additional moonlighting functions as 
suggested in L. monocytogenes. At this point, our knowledge of the underlying 
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processes that support this connection is minimal, in part due to the vast diversity 
of lipoate acquisition mechanisms that exist among species.  
 It is somewhat surprising that lipoate metabolism and its role in 
pathogenesis have not yet been explored in S. aureus, despite being one of the 
most important human pathogens. Homology-based studies revealed that S. 
aureus has a putative lipoate synthetase and several putative salvage ligases, 
indicating that this pathogen is capable of both lipoate biosynthesis and 
scavenging (16). The potential capacity to synthesize lipoate in addition to the 
unusual number of putative lipoate ligases predicted in the S. aureus genome 
open the question of whether this pathogen is capable of using different protein 
lipoylation approaches during infection. 
 Important human pathogens have been shown to use alternative sources 
of lipoate within the host (15, 61, 65) or compartmentalize the lipoylation 
mechanisms in their cells, relying on lipoate biosynthesis to lipoylate proteins in 
one organelle and supporting lipoylation through scavenging in another (14, 17, 
18). Thus, it is conceivable that S. aureus has evolved alternative strategies to 
incorporate this essential nutrient in different environments; For example, it may 
use lipoate to adapt as a commensal bacterium and survive as an invasive 
pathogen or to colonize a specific tissue and survive inside phagocytes. 
An especially intriguing connection drawn by Rack et al. is the potential 
relationship between protein lipoylation and oxidative stress responses, as well 
as the potential role of lipoate in the regulation of essential metabolic processes 
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in S. aureus (53). Furthermore, the existing evidence supporting the role of free 
lipoic acid as a redox modulator could have implications in pathogenesis, as this 
cofactor by itself could be used by S. aureus as a biological tool to cope with 
oxidative stress caused by the host defenses.  
 The answer to many of these questions, especially the role of lipoate in S. 
aureus pathogenesis, is hampered by our lack of knowledge on the mechanisms 
that this pathogen uses to lipoylate proteins. The scope of this work is to 
characterize the lipoate biosynthesis and salvage pathway in S. aureus and to 




MATERIALS AND METHODS 
Bacterial strains and culture conditions 
 All bacterial strains used in this study are listed in Table 1. S. aureus pulse 
field gel electrophoresis type USA300 isolate LAC cured of its plasmids was used 
as the parental (wild type) strain for all genetic manipulations. S. aureus 
NCTC8325 derivative RN4220, S. aureus RN9011, E. coli DH5α and DC10B 
were used as host strains for propagation of recombinant plasmids and plasmid 
integration.  
 All E. coli strains were grown in Lysogeny Broth (LB) (Amresco) 
supplemented with antibiotics as indicated below. For replication of S. aureus 
strains, Tryptic Soy Broth (TSB) (Criterion) was used as a frich medium, and 
Roswell Park Memorial Institute 1640 medium (RPMI) (Corning) supplemented 
with 1% casamino acids (Amresco) was used as a defined medium lacking 
lipoate and octanoate. Unless otherwise specified, cultures were incubated at 
37°C in a shaking incubator at 200 rpm with tubes held at a 45° angle. When 
required, LB and TSB media were solidified using 1.5% Agar (Amresco). 
 Where necessary, media were supplemented with the following antibiotics 




Table 1: List of strains used in this study 
 
 
erythromycin (ERM) at 3 µg/ml, kanamycin (KAN) at 50 µg/ml, neomycin (NEO) 
at 50 µg/ml, chloramphenicol (CM) at 10 µg/ml (Amresco), anhydrous 
tetracycline (ANTET) (Acròs Organics) at 1 µg/ml, CdCl2 (Alfa Aesar) 0.3mM, Na 
Strain Genotype Designation 
USA300 
LAC 
S. aureus USA300 Strain LAC. Plasmid cured. LAC (WT) 
DH5α E. coli strain for recombinant pIMAY and pJC plasmids  
RN4220 Restriction deficient S. aureus for plasmid passage RN4220 
RN9011 RN4220 + pRN7203 expressing SaPI integrase RN9011 
FA-S831 AH-LAC with an in-frame deletion of lipA ΔlipA 
FA-S842 AH-LAC with an in-frame deletion of lipM ΔlipM 
FA-S841 AH-LAC with an in-frame deletion of lplA1 ΔlplA1 
FA-S837 AH-LAC with an in-frame deletion of lplA2 ΔlplA2 
FA-S1176 AH-LAC with an in-frame deletion of lipL ΔlipL 
FA-S1182 AH-LAC with in-frame deletions of lipA and lipM ΔlipAΔlipM 
FA-S1249 AH-LAC with in-frame deletions of lipA and lplA1 ΔlipAΔlplA1 
FA-S1180 AH-LAC with in-frame deletions of lipA and lplA2 ΔlipAΔlplA2 
FA-S977 AH-LAC with in-frame deletion of lipA and ΔlipL:kan ΔlipAΔlipL 
FA-S912 AH-LAC with in-frame deletions of lplA1 and lplA2 ΔlplA1ΔlplA2  
FA-S1251 AH-LAC with in-frame deletions of lipM and lplA1 ΔlipMΔlplA1    
FA-S957 AH-LAC with in-frame deletion of lipM and transposon insertion in lplA2 transduced from NE266 (lipM:erm) 
ΔlipMΔlplA2  
(ΔlipM-lplA2::erm)  
FA-S994 AH-LAC with in-frame deletion of lipM and ΔlipL:kan ΔlipMΔlipL  
FA-S1210 AH-LAC with in-frame deletions of lipL and lplA1 ΔlipLΔlplA1   
FA-S998 AH-LAC with in-frame deletions of lplA2 and ΔlipL:kan ΔlipLΔlplA2   
FA-S1178 AH-LAC with in-frame deletions of lipA, lplA1, and lplA2 ΔlipAΔlplA1ΔlplA2  
FA-S992 AH-LAC with in-frame deletion of lipA, ΔlipL:kan, and transposon insertion in lipM transduced from NE1334 
ΔlipLΔlipAΔlipM 
(Δlip-LΔlipA-lipM::erm) 
FA-S1038 AH-LAC with in-frame deletion of gcvH ΔgcvH 
FA-S1041 AH-LAC with in-frame deletion of E2-PDH ΔE2-PDH 
FA-S1042 AH-LAC with in-frame deletion of E2-OGDH ΔE2-OGDH 
FA-S877 FA-S831 complemented with pJC1112-lipA ΔlipA+lipA 
FA-S1119 FA-S842 complemented with pJC1111-lipM ΔlipM+lipM 
FA-S1190 FA-S1176 complemented with pJC1111-lipL ΔlipL+lipL 
FA-S1258 FA-S1176 complemented with pJC1111-pta ΔlipL+pta 
FA-S1257 FA-S1176 complemented with pJC1111-pta-lipL ΔlipL+pta-lipL 
FA-S1206 FA-S912 complemented with pJC1111-lplA1 ΔlplA1ΔlplA2+lplA1 
FA-S1208 FA-S912 complemented with pJC1111-lplA2 ΔlplA1ΔlplA2+lplA2 
FA-S1259 FA-S1249 complemented with pJC1111-lplA1 ΔlipAΔlplA1+lplA1 
FA-S1205 FA-S1180 complemented with pJC1111-lplA2 ΔlipAΔlplA2+lplA2 
FA-S1260 FA-S1251 complemented with pJC1111-lplA1 ΔlipMΔlplA1+lplA1 
FA-S1222 FA-S1182 complemented with pJC1111-lipM ΔlipAΔlipM+lipM 
FA-S1200 FA-S1178 complemented with pJC1111-lplA1 ΔlipAΔlplA1ΔlplA2+lplA1 
FA-S1212 FA-S1178 complemented with pJC1111-lplA2 ΔlipAΔlplA1ΔlplA2+lplA2 
 
The mutant strains listed in this table were generated with the help of former and current members 
of the lab under supervision of Dr. Francis Alonzo: Azul Zorzoli (~40% of the mutant strains), Ryan 




Citrate (Sigma) 10mM. Media used for experiments in which the requirement for 
lipoate or octanoate had to be bypassed were supplemented with the following 
short branched-chain carboxylic acids (Sigma): 10.8 mM isobutyric acid, 9.2 mM 
2-methylbutyrate and 9 mM isovalerate, and 10 mM sodium acetate (Sigma). 
This medium has been previously used to bypass the metabolic requirement for 
lipoylated enzyme complexes involved in TCA cycle and branched chain amino 
acid catabolism (54) and will be referred as +BCFA throughout this document. 
Molecular genetic techniques 
S. aureus chromosomal DNA was isolated using Wizard Genomic DNA 
purification kit following the manufactures protocol (Promega). A 2 mg/ml stock 
solution of lysostaphin (Ambi Products, NY) was stored at -80°C in 20 mM 
sodium acetate, pH 4.5. For genomic DNA isolation, 2.5ul of the stock solution 
was added to a 1.2 mL culture of S. aureus that had been pelleted by 
centrifugation and resuspended in 200 ul of TSM buffer (50mM Tris, 0.5M D-
Sucrose,10 mM MgCl2 pH 7.5), followed by incubation for 15 minutes at 37°C to 
digest the cell wall. After lysostaphin treatment, the bacteria were centrifuged at 
maximum speed for 3 minutes in a microcentrifuge and bacterial DNA extracted 
following the remainder of the manufacturer’s protocol. QIAGEN Mini / Midi 
plasmid isolation kits were used to extract recombinant plasmids. DNA gel 
extraction was performed using QIAGEN QIAquick kit. Polymerase chain 
reaction (PCR) was performed in Flexid Mastercycler (eppendorf) using Phusion 
High-Fidelity DNA Polymerase (New England Biolabs), oligonucleotides from 
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Eurofins and dNTPs from Quanta Biosciences. DNA ligation was performed in 
eppendorf ThermoMixer C using T4 DNA ligase (New England Biolabs). PCR 
purification was done using a QIAquick kit from QIAGEN. Genscript performed 
sequencing. All restriction endonucleases were purchased from New England 
Biolabs.  0.8% agarose gels (Amresco) was used for DNA electrophoresis. 
E. coli competent cells preparation 
A 3 mL culture of E. coli was grown overnight at 37°C in a shaking 
incubator. The following day, the strain was subcultured at a 1:55 dilution (2 mL 
into 110 mL) of LB in a 250 mL flask. Bacteria were incubated at 37°C with 
shaking for ~2.5 hr until reaching mid-logarithmic phase (OD600 0.3 -0.4). All 
remaining steps were conducted using pre-chilled solutions, flasks, and tubes. 
Four 50 mL tubes containing 25 mL of the log-phase culture were kept on ice for 
a period of 10 min, after which they were centrifuged at 4,000 rpm for 10 min at 
4°C. Bacterial cells were harvested after decanting the supernatant and washed 
twice in 10 mL of filter-sterilized Transformation Buffer 1 (TBF-1) (30 mM KOAc, 
100 mM RbCl2, 10 mM CaCl2, 50 mM MnCl2, 15% Glycerol, adjusted at pH 5.8 
with 0.2 M Acetic Acid). Cells were incubated on ice for 10 minutes between 
washes. After a final centrifugation step at 4,700 rpm for 5 min the bacterial pellet 
was suspended in 1 mL of filter-sterilized Transformation Buffer 2 (TBF-2) (10 
mM MOPS, 10 mM RbCl2, 75 mM CaCl2, 15% Glycerol (Amresco), adjusted at 
pH 6.5 with KOH). Finally, 100 µL of the competent cells were immediately 
aliquoted into 1.5 mL microcentrifuge tubes and stored at -80°C. 
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E. coli heat transformation  
 In order to transform chemically competent E. coli, 2 µL of the ligation 
product or purified plasmid was incubated with 50 µL competent cells on ice for 
20 min. Afterwards, cells were incubated at 42°C for 45 seconds, placed on ice 
for 2 min and then suspended in 250 µL of SOC medium. (tryptone (Amresco), 
0.5 % yeast extract (Amresco), 0.05 % NaCl (Amresco) in distilled water, 
supplemented with 10% 250mM KCl (Amresco) and adjusted to a pH 7.0 using 
5M NaOH (Amresco). After autoclaving and cooling, 20% filter-sterilized 1M 
glucose solution was added. Incubation was performed with shaking at 30°C for 
1 hr, after which 100 µL of the culture was spread onto LB selection plates 
containing the required antibiotic supplements. 
Preparation of S. aureus electrocompetent cells  
 S. aureus competent cells were prepared by inoculating 300 µL of an 
overnight culture into 30 mL of fresh TSB. Cells were incubated with shaking at 
37°C for 3 hr until reaching mid-logarithmic stage followed by centrifugation at 
8,000 rpm for 10 min at 4°C. Unless indicated, cells were kept on ice throughout 
the entire process and all solutions and tubes used were pre-chilled. The 
bacterial pellet was washed 2 times in 30 mL ice-cold 10% glycerol. Cells were 
then resuspended in 15 mL 10% glycerol followed by additional centrifugation at 
8,000 RPM for 10 min to pellet the bacteria. Lastly, cells were resuspended in 3 
mL 10% glycerol and 200-500 µL aliquots were distributed into microcentrifuge 
tubes and stored at -80°C. Strains that harbored antibiotic resistance cassettes 
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were grown in media supplemented with antibiotics. Strains that showed 
impaired growth due to lipoate biosynthesis defects were grown in BCFA media.  
S. aureus transformation via electroporation  
 Transformation was performed by incubating a mixture of 50 µL of thawed 
S. aureus competent cells with 10 µL of purified plasmid (~1 µg) at room 
temperature for 30 min. Cells were transferred to a 2 mm electroporation cuvette 
(VWR) and pulsed at 1,800 V, 10 µF, and 600 Ω in a GenePulser Xcell BIORAD 
electroporator. Cells were recovered using TSB or TSB+BCFA as needed, 
transferred to a microcentrifuge tube and incubated for 1 hr and 30 min. 
Afterwards, 100 µL were spread onto TSA plates supplemented with the 
appropriate antibiotics and incubated at 30°C for 24-48 hr. 
Construction of mutagenesis vectors  
 Two fragments corresponding to ~500 nucleotides upstream (us) of the 
start codon (ATG) and ~500 nucleotides downstream (ds) from the stop codon 
(TAA) of the target gene of interest were amplified using oligonucleotide pairs 
shown in Table 2. Specifically, each us fragment was PCR amplified from wild 
type S. aureus genomic DNA using oligonucleotide #1 and oligonucleotide #2. ds 
fragments were generated using oligonucleotide #3 and oligonucleotide #4 
(Table 2). Both us and ds amplicons were purified and used as templates in a 
SOEing PCR reaction to obtain the final amplicon required for mutagenesis. 
Each amplicon of ~1000 nucleotides was subcloned into pIMAY using KpnI and 
SacI restriction endonucleases. 
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Table 2: List of oligonucleotides used in this study 
 
Name Ref Sequence Final purpose 
0829SOE1-Kpn 1 CCC-GGTACC(KpnI)-GCACAATGTGCCATCATCAA lipA deletion 
0829SOE2-Kas 2 CCTTATTAATGGTTAAATATTAACT-GGCGCC(KasI)-CGCCATAACAACACATACCC lipA deletion 
0829SOE3-Kas 3 GGGTATGTGTTGTTATGGCG-GGCGCC(KasI)-AGTTAATATTTAACCATTAATAAGG lipA deletion 
0829SOE4-Sac 4 CCC-GAGCTC(SacI)-ATTAATGTTCAGTATCTTGAATG lipA deletion 
0930SOE1-Kpn 1 CCC-GGTACC(KpnI)-GCATTATACCTGTATAAATAC lplA1 deletion 
0930SOE2-Kas 2 ATAGTCCTTTAATCGTTTATGA-GGCGCC(KasI)-TTTCATTACAATCTCTCCCTT lplA1 deletion 
0930SOE3-Kas 3 AAGGGAGAGATTGTAATGAAA-GGCGCC(KasI)-TCATAAACGATTAAAGGACTAT lplA1 deletion 
0930SOE4-Sac 4 CCC-GAGCTC(SacI)-ATAAGCAAAACCTCGCTTTAT lplA1 deletion 
0328SOE1-Kpn 1 CCC-GGTACC(Kpn1)-TATTTCATATACAAGGGGAGTATA lplA2 deletion 
0328SOE2-Kas 2 CATACATAAAATAACAATATTAACT-GGCGCC(KasI)-GTACATCTTCTGTCTCTCCA lplA2 deletion 
0328SOE3-Kas 3 TGGAGAGACAGAAGATGTAC-GGCGCC(KasI)-AGTTAATATTGTTATTTTATGTATG lplA2 deletion 
0328SOE4-Sac 4 CCC-GAGCTC(SacI)-CTTGTGATAAATCCGCTTCG lplA2 deletion 
1494SOE1-Kpn 1 CCC-GGTACC(KpnI)-TTATAGCCGCCTTTTAACATA lipM deletion 
1494SOE2-Kas 2 CATTTTTTATTCTAAAAACTACTT-GGCGCC(KasI)-AGTCATATTCAAGAACTCCTA lipM deletion 
1494SOE3-Kas 3 TAGGAGTTCTTGAATATGACT-GGCGCC(KasI)-AAGTAGTTTTTAGAATAAAAAATG lipM deletion 
1494SOE4-Sac 4 CCC-GAGCTC(SacI)-ATATTCAAAGTGCTCACACTT lipM deletion 
0571SOE1-Kpn 1 CCC-GGTACC(KpnI)-AAGTGCAAAATCAGCATTAAG lipL deletion 
0571SOE2-Kas 2 GGCTGTTAAATATTTAACTATTG-GGCGCC(KasI)-TTGCATAGGTTCTAATCCAG lipL deletion 
0571SOE3-Kas 3 CTGGATTAGAACCTATGCAA-GGCGCC(KasI)-CAATAGTTAAATATTTAACAGCC lipL deletion 
0571SOE4-Sac 4 CCC-GAGCTC(SacI)-GTTGCATACGCATTCTCGT lipL deletion 
0791SOE1-Kpn 1 CCC-GGTACC(KpnI)-AGGTTGCAGTCGTATGATTA gcvH deletion 
0791SOE2-Kas 2 ATTAAGGAGTTACACGGTGA-GGCGCC(KasI)-GAGAATCCCCTCCTAATTAA gcvH deletion 
0791SOE3-Kas 3 TTAATTAGGAGGGGATTCTC-GGCGCC(KasI)-TCACCGTGTAACTCCTTAAT gcvH deletion 
0791SOE4-Sac 4 CCC-GAGCTC(SacI)-CAGACATTCCATACATTTGATC gcvH deletion 
0995SOE1-Kpn  CCC-GGTACC(KpnI)-TGAAGAAGTACCTGAAGAAG e2-pdh deletion 
0995SOE2-Kas 2 GAAATCTCCAACTACCATGTT-GGCGCC(KasI)-GTTTTTGCCCTCCTAAGATT e2-pdh deletion 
0995SOE3-Kas 1 AATCTTAGGAGGGCAAAAAC-GGCGCC(KasI)-AACATGGTAGTTGGAGATTTC e2-pdh deletion 
0995SOE4-Sac 4 CCC-GAGCTC(SacI)-TACTTCTTGTAAGTTTAAAGCA e2-pdh deletion 
1305SOE1-Kpn 1 CCC-GGTACC(KpnI)-TGCACAAGCGGCTAGTTTA e2-ogdh deletion 
1305SOE2-Kas 2 TAAACTATTTTGTGTTGTGGA-GGCGCC(KasI)-GACTTATTTCCCCCTAGTTA e2-ogdh deletion 
1305SOE3-Kas 3 TAACTAGGGGGAAATAAGTC-GGCGCC(KasI)-TCCACAACACAAAATAGTTTA e2-ogdh deletion 
1305SOE4-Sac 4 CCC-GAGCTC(SacI)-AATCATAAATTATAGAATATCGG e2-ogdh deletion 
1464SOE1-Kpn 1 CCC-GGTACC(KpnI)-GCTAAAGGGCTTTTATTATCA e2-bcodh deletion 
1464SOE2-Kas 2 ATAGATGCATCTATGTTATCA-GGCGCC(KasI)-ACTTTCCCTCCCTAGAATT e2-bcodh deletion 
1464SOE3-Kas 3 AATTCTAGGGAGGGAAAGT-GGCGCC(KasI)-TGATAACATAGATGCATCTAT e2-bcodh deletion 
1464SOE4-Sac 4 CCC-GAGCTC(SacI)-GCTGGTCTTGCGATACCA e2-bcodh deletion 
KanF-Kas  TCCC-GGCGCC(KasI)-CTCGACGATAAACCCAGCGAAC KanR cassette insertion 
KanR-Kas  TCCC-GGCGCC(KasI)-CTTTTTAGACATCTAAATCTAGGTAC KanR cassette insertion 
0829CompF-Bam  GGC-GGATCC(BamHI)-GTAAGATTATTGGATTTTCATTT lipA complement 
0829CompR-EcoRI  GGC-GAATTC(EcoRI)-CTATCTATGACAATGAAAGG lipA complement 
UniCompSOE1-Pst C1 ATAT-CTGCAG(PstI)-ATCCCATTATGCTTTGGCA PHELP amplification 
0328CompSOE2 C2 AATCGGTTCTATTAAGTACATGGGTTTCACTCTCCTTCTA PHELP amplification 
0328CompSOE3 C3 TAGAAGGAGAGTGAAACCCATGTACTTAATAGAACCGATT lplA2 complement 
0328CompSOE4-Sac C4 ATAT-GAGCTC(SacI)-TAGAAACAAAAACCATATATATA lplA2 complement 
0930CompSOE2 C2 ATTATTATTACTAATGAATTTCATGGGTTTCACTCTCCTTCTA PHELP amplification 
0930CompSOE3 C3 TAGAAGGAGAGTGAAACCCATGAAATTCATTAGTAATAATAAT lplA1 complement 
0930CompSOE4-Sac C4 ATAT-GAGCTC(SacI)-ACTATTCTTAACATCTCATAC lplA1 complement 
1494CompSOE2 C2 AAAATTCCAAGTTTCAGTCATGGGTTTCACTCTCCTTCTA PHELP amplification 
1494CompSOE3 C3 TAGAAGGAGAGTGAAACCCATGACTGAAACTTGGAATTTT lipM complement 
1494CompSOE4-Sac C4 ATAT-GAGCTC(SacI)-TGTAGGTAAAATAGTCTACG lipM complement 
0571CompSOE2 C2 CGAATGCGAAAGATTGCATGGGTTTCACTCTCCTTCTA PHELP amplification 
0571CompSOE3 C3 TAGAAGGAGAGTGAAACCCATGCAATCTTTCGCATTCG lipL complement 
0571CompSOE4-Sac C4 ATAT-GAGCTC(SacI)-AAAAATAACAGCCCCAAACG lipL complement 
ptaSOE1-Pst C1 ATAT-CTGCAG(PstI)-ATCCCATTATGCTTTGGCA PHELP amplification 
ptaSOE2 C2 ATACATTTAATAAATCAGCCATGGGTTTCACTCTCCTTCTA pta complement!
ptaSOE3 C3 TAGAAGGAGAGTGAAACCCATGGCTGATTTATTAAATGTAT pta complement!
ptsSOE4 C4 ATAT-GAGCTC(SacI)-TTATTGTAAGGCTTGCGCT pta complement 
pta-0571SOE1-Pst C1 ATAT-CTGCAG(PstI)-ATCCCATTATGCTTTGGCA PHELP amplification 
pta-0571SOE2 C2 ATACATTTAATAAATCAGCCATGGGTTTCACTCTCCTTCTA pta lipL compl. 
pta-0571SOE3 C3 TAGAAGGAGAGTGAAACCCATGGCTGATTTATTAAATGTAT PHELP amplification 




Generation of in-frame deletion mutants  
 Briefly, recombinant pIMAY containing 500 bp regions of homology us and 
ds of the target gene were transformed into S. aureus LAC via electroporation 
and propagated at 28-30°C in the presence of chloramphenicol. Plasmid 
recombination into the chromosome was induced by shifting to 37°C, a non-
permissive temperature for pIMAY replication, in the presence of 
chloramphenicol. Plasmid integrants were then incubated at 30°C without 
antibiotics, to induce plasmid replication and excision from the chromosome. 
Bacteria were subsequently plated on medium containing anhydrous tetracycline 
(AnTet), which induces the expression of a secY antisense RNA transcript under 
control of the Pxyl/tetO promoter and serves as an effective counter-selection 
against any S. aureus still harboring pIMAY. Following counter-selection, 
chloramphenicol sensitive bacteria were screened for the presence of the desired 
mutation by PCR. 
Construction of marked deletion mutants 
 To overcome difficulties encountered when generating mutants with 
growth deficiencies (lipL, e2-pdh, e2-ogdh, and gcvH), we constructed 
mutagenesis plasmids containing an antibiotic resistance marker, aphA (kanR). 
The kan resistance gene was PCR amplified from plasmid pBTK with 
oligonucleotides TCCC-GGCGCC-CTCGACGATAAACCCAGCGAAC and 
TCCC-GGCGCC-CTTTTTAGACATCTAAATCTAGGTAC and sub-cloned into a 
unique KasI site engineered between the us and ds regions of 
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homologypreviously cloned into pIMAY. Once constructed, the pIMAY gene 
replacement constructs were transformed into wild type S. aureus as described 
above. Allelic replacement was carried out as already described and gene 
replacement mutants were selected on Kan/Neo plates. This procedure was 
used to generate the following mutant strains: ΔlipL::kan, Δe2-pdh::kan, Δe2-
ogdh::kan, and ΔgcvH::kan. 
Construction of lipL markerless deletion mutant 
The first attempts to construct clean deletions of lipL failed to yield 
mutants, likely due to the role of LipL in supporting the function of essential 
metabolic pathways in S. aureus. To generate this growth-defective mutant 
strain, we constructed the above-mentioned gene replacement mutant carrying 
an antibiotic selection marker in place of lipL. This initial strain, ΔlipL::kan, was 
then used as parental strain to construct a ΔlipL clean deletion mutant as well as 
ΔlipAΔlipMΔlipL. The excision of the antibiotic resistance gene was achieved by 
using pIMAY containing lipL us and ds 500bp regions of homology, constructed 
as described above leading to the generation of a ΔlipL mutant strain, whose 
identity was validated by DNA sequencing. 
Construction of ΔlipM ΔlipL 
 ΔlipL::kan was introduced into ΔlipM via generalized transduction using 
bacteriophage ϕ11. The transduction process is described later in this section, in 




Construction of ΔlipM ΔlplA2  
 ΔlipM ΔlplA2 was constructed by transducing ΔlplA2::erm mutation into 
ΔlipM using bacteriophage ϕ11. ΔlplA2::erm (NE266) was obtained from the 
University of Nebraska USA300 S. aureus bursa aurealis transposon mutant 
library. 
Construction of ΔlipA Δlip MΔlipL  
 This mutant was generated from S. aureus LAC with an in-frame deletion 
of lipA that was transduced with both a transposon inserted into lipM, obtained 
from NE1334 (lipM::erm), and the lipL deletion mutant bearing a kanamycin 
resistance cassette (ΔlipL::kan). All transductions were conducted using 
bacteriophage ϕ11, generating ΔlipA ΔlipM ΔlipL.  
Bacteriophage-mediated generalized transduction 
 S. aureus specific bacteriophage ϕ11 was used for all transductions. To 
package phage with donor DNA, a 3 mL overnight culture of the donor strain 
containing the marked gene of interest was incubated with shaking at 37 °C in 
TSB-LB media (mixed 1:1) supplemented with 5mM CaCl2 and 5mM MgSO4. The 
overnight culture was diluted 1:100 into 10 mL of TSB-LB media supplemented 
with 5 mM Cacl2 and 5 mM MgSO4, and was then grown at 37°C in the shaking 
incubator for 2.5-3 hours, until reaching a OD 600 nm of 0.3 to 0.9. After this 
step, 500 µL of bacterial culture were incubated at room temperature with 10-fold 
serial dilutions of ϕ11 phage lysate stock in TMG (10 mM Tris pH 7.5, 5 mM 
MgCl2, 0.01% gelatin (v/v)), aiming to achieve an approximate multiplicity of 
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infection of 1:1. After 30 minutes, the tubes containing the bacterial suspension 
and the phage dilutions were mixed with 3 mL of CY Top agar (Casamino acids 5 
g/L, Yeast Extract 5 g/L glucose 5 g/L NaCl 6g/L, 7.5 g/L agar, +/- BCFA as 
needed) cooled at 55°C and supplemented with 5 mM CaCl2 and 5 mM MgSO4 
and immediately poured on TSA (+/-BCFA as needed) plates supplemented with 
the corresponding antibiotic. Once solidified, plates were incubated overnight at 
30°C. Following overnight growth, the top agar of 2-3 plates was scraped from 
those with confluent plaques using a sterile scoopula and introduced into a single 
50 ml tube. Top agar was then suspended in 2 mL of phage buffer (TMG) per 
plate worth of Top agar. After extensive vortexing, the tubes were centrifuged for 
15 min at maximum speed and the supernatant was filter-sterilized twice using 
0.45 µm and 0.22 µm filters. Phage stocks were stored at 4°C.  
 To transduce recipient strains, overnight cultures containing 20 mL of the 
recipient cells in TSB:LB supplemented with 5mM CaCl2 were centrifuged at 
maximum speed for 15 min and resuspended in 3 mL TSB:LB media (1:1), also 
supplemented with 5 mM CaCl2. Phage infection was carried out by incubating 
500 µL serial dilutions (1; 1:10; 1:100) of the bacterial suspension with either 100 
µL of ϕ11 phage (108-109 PFU) or 100 µL of TMG buffer (control uninfected) at 
room temperature for 30 min, inverting the tubes every 10 min. After incubation, 
40 mM final sodium citrate were added to the tubes from a 1M stock solution and 
samples were incubated for an additional 30 min period, inverting tubes every 10 
min. Samples were then centrifuged at maximum speed for 5 min and washed in 
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500 µL LB:TSB medium supplemented with 40mM final sodium citrate. After a 
second centrifugation step cells were resuspended in 200 µL TSB containing 40 
mM final sodium citrate and 100 µL were spread onto TSA BCFA plates 
containing 10 mM sodium citrate supplemented with the necessary antibiotics. 
Plates were incubated at 30°C for 24-48 hr or until detection of bacterial colonies. 
Potential transductants were later validated via PCR. 
Generation of complemented strains 
 S. aureus complementation strains were generated using plasmid 
pJC1111(66) for all strains, except for complementation with lipA, for which we 
used the vector pJC1112 (67). These vectors were propagated in E. coli DH5α 
and selected for ampicillin resistance. Both pJC1111 and pJC1112 stably 
integrate into the SaPI-1 site of the S. aureus chromosome after passage 
through strain S. aureus RN9011 containing pRN7203 expressing SaPI-1 
integrase, leading to single-copy stable integration of the plasmid.  
 In order to generate complementation strains using pJC1111 we first 
generated constructs that drive expression of the lipM, lipL, pta, pta-lipL, lplA1 or 
lplA2 genes under the control of the constitutive PHELP promoter obtained from 
pIMAY (68). All oligonucleotides designed for amplification of these complement 
constructs are listed in Table 2. Primers designated as C1 and C2 were used to 
amplify the PHELP promoter using pIMAY as template DNA. Primers identified as 
C3 and C4 were used to amplify the open reading frame corresponding to the 
gene of interest for complementation including ~150 nucleotides ds. These two 
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DNA fragments were joined via SOEing PCR as described above. All amplicons 
were subsequently purified and cloned into pJC1111 after digestion with 
restriction enzymes Pst1 and Sac1 and subsequent ligation into pJC1111 
generating pJC1111-lipM, pJC1111-lipL, pJC1111-lplA1, pJC1111-lplA2, 
pJC1111-pta and pJC1111-pta-lipL.  
 All complementation plasmids were propagated in E. coli DH5α, followed 
by isolation and subsequent electroporation into S. aureus RN9011 and plating 
on TSA+BCFA plates supplemented with chloramphenicol and CdCl2. Integrants 
were selected based upon CMr CdCl2r and were used as donor strains to 
package and transduce the complementation allele into the desired mutant 
strain. Complemented strains were selected based on their CdCl2 resistance and 
validated via PCR. This process resulted in the generation of strains ΔlipM+lipM; 
Δlipl+lipl; ΔlipL+pta; ΔlipL+pta-lipL; ΔlipAΔlplA1+lplA1; ΔlipAΔlplA2+lplA2; 
ΔlipMΔlplA1+lplA1; ΔlipAΔlipM+lipM; ΔlipAΔlplA1ΔlplA1+lplA1, and 
ΔlipAΔlplA1ΔlplA1+lplA2. 
 Complementation of ΔlipA was accomplished by amplification of the lipA 
gene with its native promoter using primers 0829CompF-Bam and 0829CompR-
EcoRI. The resultant amplicon was cloned into pJC1112 after digestion with 
enzymes BamHI and EcoRI. Plasmid propagation in E. coli DH5α was performed 
as described above and pJC1112-lipA was subsequently electroporated into S. 
aureus RN9011. The chromosomally integrated complementation vector was 
later packaged into bacteriophage ϕ11 and transduced into a ΔlipA background. 
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Positive transformants were selected based on their erythromycin resistance (3.5 
µg/mL) and designated ΔlipA+lipA. 
Requirement of lipoate or octanoate for bacterial growth  
 Bacterial growth curves were carried out in four types of media: RPMI, 
RPMI+BCFA, RPMI+Lipoate and RPMI+Octanoate. Overnight cultures were 
prepared in triplicate from three individual colonies by inoculating 200 µL of 
RPMI+BCFA in adjacent wells of a round-bottom 96-well polystyrene plate 
(Corning) followed by incubating overnight with shaking at 200 RPM at 37°C. The 
following morning, cells were pelleted at 3,700 rpm for 15 min and washed three 
times with 200 µL of RPMI to remove any remaining branched chain carboxylic 
acids. After washing cells, 2 µL of each triplicate sample was inoculated into flat-
bottom polystyrene 96-well plates (Corning) containing 198 µL of RPMI, 
RPMI+BCFA, RPMI+25 nM of α-Lipoic acid (Sigma) or RPMI+250 µM Octanoic 
acid (Sigma). Bacterial growth was assessed over time by measuring optical 
density at 550 nm (OD550), using microplate reader ELx800 (Biotech) until 
reaching stationary phase (9-10 hours). Results were graphed and analyzed 
using Prism® (GraphPad Software, Inc., San Diego, CA). All growth curves were 
conducted at least three times in triplicate. The mean optical density at 550 nm 
and standard deviation are shown for all curves. 
Whole cell lysate preparation 
 S. aureus wild type and mutant strains were grown overnight with shaking 
at 37°C in 15 mL conical tubes containing 5 mL of RPMI+BCFA media. A 
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subculture of 60 µL of these samples was inoculated into 15 mL conical tubes 
containing 6 mL of RPMI+BCFA, RPMI+BCFA+5 µM α-Lipoic acid, or 
RPMI+BCFA+170 µM Octanoic acid. Samples were incubated with shaking at 
200 RPM for 9 hr and bacterial growth was determined by measuring optical 
density at 600nm with 1 mL of the culture using a Genesys 10S UV-Vis 
spectrophotometer (Thermo). The remaining culture volume was centrifuged at 
4,200 rpm for 15 min, the supernatant was discarded, and the bacterial pellets 
were stored at -80°C until whole cell lysates were prepared. After thawing frozen 
pellets on ice, the bacteria were suspended in 250 µL of PBS and transferred to 
screw cap microcentrifuge lysing tubes (Fisher Scientific) containing 250 µL 
0.1mm glass cell disruption beads (Scientific Industries, Inc.). Cells were lysed 
using a Fast Prep-24 5G (MP Biomedicals) in two sequential steps, at 5.0 speed 
for 20 seconds and at 4.5 speed for 20 seconds, each separated by a 5 min 
incubation period on ice. After cell disruption, samples were centrifuged at 
13,000 rpm for 15 min. 130 µL of the supernatant were collected in 
microcentrifuge tubes containing 43 µL of 6X SDS loading buffer (1.11mL 0.9M 
Tris-HCl pH 6.8; 0.16g SDS; 2 mL 100% Glycerol; 0.2 mL 14.7M BME; 0.5 mL 
0.5 M EDTA, 4 mg bromophenol blue in a 10 mL final volume) and samples were 
boiled for 10 min prior to storage at -20 C. 
Protein lipoylation assessment 
 Proteins samples from OD-normalized whole cell lysates were separated 
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in 
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12% polyacrylamide gels at 120 volts for approximately 4 hours. Coomassie 
staining was performed to evaluate protein patterns and equivalent loading of 
samples using GelCode Blue stain reagent (Thermo) with Precision Plus Protein 
Ladder™ (Thermo) used as a molecular weight marker. Briefly, resolved proteins 
were transferred from polyacrylamide gels to 0.2 µm PVDF membranes 
(Immobilon, Roche) at 200 V for 1 hr in a Quadra Mini-Vertical PAGE/Blotting 
System (CBS Scientific). After transfer, membranes were incubated overnight 
with PBST (0.1% Tween-20 in PBS) supplemented with 5% BSA at 4°C. 
Nonspecific binding of antibody to S. aureus antibody binding proteins, Protein A 
and Sbi, was blocked by incubating the membranes with 0.9 mg/mL human IgG 
(Sigma) for 1hr. A 1:3000 dilution of rabbit polyclonal anti-lipoic acid antibody 
(Calbiochem) in PBST was added to the membrane followed by incubation for 1 
hour and three subsequent washed in ~20mL of PBST. Goat anti-Rabbit IgG 
(H+L) HRP conjugate (Thermo) was then added at a 1:200 dilution in PBST for 
an additional hour followed by three 15 minutes washes in ~20 mL of PBST. 
Western blot images were captured on a FluorChem System (Protein Simple) 
using SuperSignal West Pico Chemiluminiscent Substrate (Thermo). 
Murine systemic infections 
All animal experiments were performed in ABSL2 facilities with protocols 
approved by Loyola University of Chicago in accordance with the standards of 
the Institutional Animal Care and Use Committee. Each experiment was 
performed at least three times with cohorts of at least 4 animals. Overnight 
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cultures of each strain were inoculated from freshly isolated single colonies 
struck out from the freezer the day prior and grown with shaking at 37°C for ~16 
hours. A 1:100 subculture into 15 mL of TSB+BCFA was performed followed by 
incubation with shaking at 200 rpm, 37°C for 3-4 hr (until reaching optical density 
at 600 nm near 1.0). Cultures were then centrifuged for 5 minutes at maximum 
speed in a tabletop centrifuge. Cell pellets were washed twice in 5 mL PBS and 2 
mL of the final bacterial suspension was added to a 15 mL conical tube 
containing 8 mL of PBS. Bacterial suspensions were then normalized with PBS 
to reach to an O.D. of 0.32 - 0.33 (1 x 108 CFU/mL). Six to eight week old female 
Swiss Webster mice obtained from Envigo (formerly Harlan) were used in all 
experiments. Mice were deeply anesthetized with 2,2,2-tribromoethanol (Avertin; 
Sigma) via intraperitoneal injection, followed by inoculation with 100 µL PBS 
containing 1 x 107 CFU wild type S. aureus or mutant strains directly into the 
bloodstream via injection into the retro-orbital venous plexus. After infection, the 
remaining bacterial-PBS suspension was plated on TSA-BCFA plates to ensure 
viability of cells in PBS and accurate infection inoculum. All strains were fully 
viable in PBS and all animals received between (1.0 and 2.0 x 107 CFU). Infected 
mice were monitored daily and their kidneys and hearts were isolated 
immediately after euthanasia, at 96 hr post infection. Tissues were aseptically 
isolated, homogenized and spread onto TSA-BCFA agar plates and incubated 





Data analysis was performed via nonparametric 1-way ANOVA using 
Prism Graphpad Software V.7 with evaluation of statistical significance done with 
Krustal-Wallis multiple comparison post-test. N values in mice experiments are 
indicated in the corresponding figures. Growth curves were conducted at least 
three times and each one was generated from three independent single colonies. 
For each experiment, mean and standard deviations of each data point were 
obtained after averaging the values in optical densities. Immunoblots were 
conducted a minimum of four times from freshly prepared samples of whole cell 





 EXPERIMENTAL RESULTS 
Introduction 
 Staphylococcus aureus is both a skin commensal bacterium and one of 
the most relevant human bacterial pathogens, capable of causing minor 
infections and life-threatening diseases. In the last few years, there has been an 
increase in the onset of S. aureus community-acquired infections, some of which 
are caused by hypervirulent strains with an unusual resistance to antimicrobials. 
The reason that S. aureus is such a versatile and efficient pathogen stems from 
its production of an artillery of virulence factors, along with its ability to hunt for 
essential metabolites in nutritionally restricted environments (1, 7). 
 In a transposon mutagenesis screen designed to identify novel genes with 
potential immunomodulatory or virulence functions, Dr. Alonzo identified a 
transposon insertion in the gene SAUSA300-0829, encoding a putative lipoate 
synthetase (lipA). Supernatant derived from this transposon mutant elicited a 
hyper inflammatory response in vivo and in vitro (unpublished data), suggesting a 
potential link between lipoate biosynthesis in S. aureus and pathogenesis. 
Based on the information available from other bacterial species that harness 
lipoate biosynthesis for pathogenesis, and considering the major role for lipoate 
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in metabolism in bacterial survival, we hypothesize that the mechanisms of 
lipoate acquisition in S. aureus contribute to fitness and pathogenesis by 
promoting survival in infectious sites with limited access to lipoate.  
Until now, the mechanisms of lipoate biosynthesis and salvage, as well as 
the role of lipoate in S. aureus infection biology, remain unknown. The work in 
this thesis aimed to address these topics. 
The model pathway for lipoate acquisition 
The mechanisms of lipoylation in bacteria were first described in 
Escherichia coli, considered the model organism on which studies of lipoate de 
novo biosynthesis and salvage are based. However, more recent work using 
Listeria monocytogenes and Bacillus subtilis revealed significant differences in 
the lipoate biosynthesis and salvage pathways of these microorganisms, 
suggesting divergence from those of E. coli (16). Due to the moderate amino acid 
sequence similarities of S. aureus lipoate biosynthesis and salvage genes 
compared to that of E. coli, our work instead derives from comparisons to B. 
subtilis lipoate ligases and biosynthesis genes. A simplified pathway for the B. 
subtilis lipoate biosynthesis and salvage pathways is depicted in Figure 2. 
 In B. subtilis, the endogenous synthesis of lipoate occurs in two sequential 
steps catalyzed first by an octanoyl transferase (LipM) and then by a lipoate 
synthetase (LipA). The first step consists of transferring an octanoate group from 
an octanoylated acyl carrier protein (ACP) to a target E2 or H protein subunit. 
The second step entails the synthesis of lipoate via the insertion of two sulfur 
atoms into the octanoate backbone by LipA. Additionally, B. subtilis requires a 
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third enzyme for lipoylation of the target proteins known as LipL, a lipoyl 
transferase. By using its lipoate salvage pathway, B. subtilis can bypass both 
octanoyl transferase and the lipoate synthetase activities using LplJ, a lipoate 
ligase capable of scavenging free lipoate and octanoate from environmental 
sources.  
 Based on the comparison of amino acid identity of S. aureus USA300 
isolate FPR3757 lipoate biosynthesis/salvage pathway, this pathogen appears to 
be more complex than most other Gram-positive pathogens. Current gene 
annotations suggest that S. aureus encodes four putative lipoate ligases and one 
lipoate synthetase. According to this annotation, S. aureus would not encode an 
octanoyl transferase or a lipoyl transferase. Nevertheless, our bioinformatics 
analyses revealed similarities to B. subtilis enzymes involved in de novo lipoate 
biosynthesis and salvage and to L. monocytogenes lipoate ligases (. 
 
Table 3 and Fig. 16 Appendix II). For instance, in S. aureus a number of gene 
products annotated as lipoate ligases exhibit significant amino acid sequence 
identity to B. subtilis: SAUSA-300-0571 54% similarity to LipL and SAUSA300-
1494 has 62% identity to LipM, indicating that some of these gene products might 
be lipoyl/octanoyl transferases. Additionally, in contrast to B. subtilis, which only 
has one lipoate ligase (LplJ), S. aureus appears to have two gene products, 0328 
and 0930, with predicted ligase functionality. The amino acid sequence alignment 
shows that SAUSA-300-0328 has 39% similarity, while SAUSA-300-0930 has 
57% amino acid sequence identity to B. subtilis LplJ. 
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 The presence of several putative lipoate ligases and a lipoate synthetase 
in the genome of S. aureus implies that this pathogen uses both the de novo 
biosynthesis and salvage pathways to acquire lipoate. Interestingly, the existence 
of two putative ligases in S. aureus genome is a unique characteristic that 
distinguishes this species from other Gram-positive pathogens. The presence of 
more than one lipoate ligase is a feature most commonly associated with 
organisms that lack a de novo lipoate biosynthesis pathway, such as L. 
monocytogenes (16, 19). When we compared 0930 and 0328 with the sequences 
coding for L. monocytogenes lipoate ligases, we observed that S. aureus putative 
lipoate ligases genes had a moderate (37-41%) amino acid sequence similarity to 
L. monocytogenes LplA1 and LplA2 (Table 3 and Fig. 16 Appendix II). This 
information may imply that S. aureus encodes two lipoate ligases in addition to 
potentially having the enzymes required for lipoate de novo biosynthesis.  
 Our bioinformatics analyses revealed a number of distinct genes with 
potential novel roles in lipoate metabolism within the genome of S. aureus that 
deserved further investigation; Figure 3 depicts their genomic localization and 
operon organization. For clarity purposes, we have decided to adopt relevant B. 
subtilis and L. monocytogenes nomenclatures. Thus, S. aureus genes potentially 
involved in lipoate de novo biosynthesis (0829, 1494 and 0571) are named 
according to B. subtilis classification (lipA, lipM and lipL, respectively) and the 
genes potentially involved in lipoate salvage (0930 and 0328) are named 




Table 3: S. aureus putative genes involved in lipoate metabolism 
S. aureus 
annotation Gene Product 




0829 (LipA) LipA - Lipoate synthetase (79%) 
Lipoate 
Ligase 
1494 (LipM) LipM - Octanoyl transferase (62%) 
0571 (LipL) LipL - Lipoyl transferase (54%) 
0930 (LplA1) LplJ - Lipoate ligase (57%) 
0328 (LplA2) LplJ - Lipoate ligase (39%) 
 
In addition to their similarity to B. subtilis LplJ, the putative lipoate ligases 0930 and 0328 share 
between 37%-41% amino acid identity with L. monocytogenes lipoate ligases LplA1 and LplA2. 
Due to the fact that S. aureus potentially encodes two lipoate ligases and not one, we have 
decided to adopt the nomenclature established for L. monocytogenes for the genes involved in 
lipoate salvage. Thus, genes 0930 and 0328 will be referred as LplA1 and LplA2. 
 
 The fact that the two ligases in L. monocytogenes have different affinities 
for lipoylated peptides in vivo (15) suggests potential unique functions for the S. 
aureus lipoate ligases in fitness and pathogenesis. 
 Of note, two genes associated with lipoate metabolism in S. aureus were 
found in operon arrangements. Our bioinformatics analysis of S. aureus gene 
arrangements showed that lipL gene is clustered in a putative operon with the pta 
gene, presumably responsible to encode the phosphotransacetylase in S. 
aureus. Pta is linked to the acetyl CoA kinase (ACKA); together they catalyze the 
reversible interconversion of acetyl CoA to acetate and ATP during overflow 
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metabolism. The S. aureus 0328 (lplA2) putative lipoate ligase gene is the 
second gene with a unique genetic arrangement in the chromosome. It is located 
in an extended operon that encodes the sirtuin SirtM and its macrodomain, along 
with GcvH-L (53). Interestingly, LplA2 modifies GcvH-L in a lipoylation reaction 
that precedes the reversible modification of GcvH-L via SirtM (53).  
 In a few bacterial and malarial pathogens lplA orthologs can be found near 
the genes that encode for E2-PDH and other lipoylated complexes (16). This 
association could, in principle, facilitate the association between a lipoate 
enzyme to its target proteins. Whether these unique genetic arrangements are 
involved in additional functions or regulation of metabolic processes remains to 
be tested. 
In this study, I planned to determine the biological role of the components 
of the lipoate de novo biosynthesis and salvage pathway in S. aureus in order to 
fully establish the mechanisms used to acquire this essential cofactor. 
Specifically, I aimed to test the hypothesis that not all S. aureus genes annotated 
as lipoate ligases are actually involved in lipoate salvage, but rather have 
functions related to either lipoate salvage or de novo biosynthesis. Also, I 
proposed to study the requirement for this pathway in S. aureus aerobic growth. 
Lastly, I aimed to determine whether lipoate de novo biosynthesis and salvage 









Figure 3: Genome organization of S. aureus lipoate predicted genes 
Boxed arrows indicate open reading frames. LplaA2 is encoded in the SirTM operon (53). The 
gene encoding the putative lipoyl transferase (amidotransferase) LipL is located in an operon with 
the gene coding for the enzyme phosphotransacetylase. The following flanking genes do not 
seem to be relevant to lipoate metabolism or regulation: hbp: heme binding protein; mvk-




For clarity purposes and based in the information provided above, we 
propose the following hypothetical pathway for the acquisition of lipoate via de 
















Figure 4: Hypothetical lipoate de novo biosynthesis and salvage pathway 
This is a simplified model for lipoate de novo biosynthesis and salvage in S. aureus. Lipoate 
biosynthesis is catalyzed by a lipoate synthetase (LS) prior octanoylation of GcvH by an octanoyl 
transferase (OT). Lipoyl groups are subsequently transferred to E2 subunits of target proteins by 
a lipoyl transferase (LT). In the salvage pathway, lipoate is incorporated from the environment 
through the action of lipoate ligases (LPL) 
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Construction of deletion mutants to study S. aureus lipoate 
pathway 
 We constructed nonpolar in-frame deletion mutants of all five genes 
predicted to be involved in lipoate acquisition, as well as their corresponding 
complementation strains to evaluate the requirement for each gene in de novo 
lipoate biosynthesis. Based on our bioinformatics analyses, we anticipated the 
single deletion mutants of the putative lipoate ligases, ΔlplA1 and ΔlplA2, would 
not be sufficient to elucidate the biological role of these enzymes, since these 
mutant strains would still be capable of generating lipoate de novo due to the 
presence of lipA in each strain. Therefore, in order to ascertain the function of the 
lipoate ligases, we also needed to construct double and triple in-frame deletion 
mutants of both ligase genes in the background of a lipA deletion mutant. Lastly, 
to fully dissect the steps in S. aureus protein lipoylation, we also generated 
double deletion mutants of the putative lipoate ligases in both ΔlipM and ΔlipL 
genetic backgrounds. As required, we generated complementation strains for all 
biosynthesis and salvage mutants displaying phenotypic variances from wild 
type. 
 Table 1 lists the mutant strains generated to fully dissect S. aureus de 
novo biosynthesis and salvage pathways. Unless indicated, all strains were 
generated by myself or with the assistance of others in the lab. The table also 
includes our WT strain USA300 LAC, E. coli DH5α, S. aureus RN4220 and S. 
aureus RN9011, all of which were required to propagate plasmids and for the 
construction of mutants or their complements. Table 2 lists the oligonucleotides 
52 
	  
used for mutant and complemented strains. For the generation of mutant strains 
with growth deficiencies (lipL, e2-pdh, e2-ogdh, and gcvH), we conducted 
mutagenesis using plasmids containing a kanamycin resistance marker.  
Identification of the lipoylated protein subunits in S. aureus 
 To elucidate the lipoate de novo biosynthesis and salvage pathway in S. 
aureus, we assessed in-frame deletion mutants of the putative genes involved in 
lipoate metabolism for their ability to replicate and lipoylate metabolic E2 and H 
subunits. As mentioned previously, the literature suggests that S. aureus 
possesses four lipoate-containing multienzyme complexes, PDH, OGDH, 
BCODH and GCS, each bearing a lipoate molecule attached to a core E2 or H 
subunit (16). These lipoylated subunits can be detected as four distinct bands in 
immunoblots of S. aureus whole cell lysates using anti-lipoic acid antibody. 
GcvH-L, the protein described by Rack et al. (53) 
  To determine the identity of the four lipoylated proteins detected in S. 
aureus whole cell lysates, we evaluated the lipoylation profiles of ΔE2-pdh, ΔE2-
ogdh and ΔgcvH (H subunit of the glycine cleavage complex) mutants (Figure 5). 
constructed by James Grayczyk, a current member of our lab. Unfortunately, 
generation of a ΔE2-bcodh mutant was unsuccessful, which suggests a major 
role of the branched-chain 2-Oxoacid dehydrogenase complex in maintaining S. 
aureus viability. If E2-pdh, E2-ogdh, and gcvH encode proteins that get lipoylated 
in S. aureus, then we should see an absence of lipoylation corresponding to the 
product encoded by that gene, regardless of whether or not lipoate is 
supplemented exogenously.  
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  Wild type S. aureus lipoylates four protein species at 72, 65, 51, and 23 
kilodaltons (Figure 5). After deletion of the E2 subunit of PDH, the ~72 kDa band 
is no longer detectable. When we tested ΔE2-ogdh in the presence or absence of 
lipoate supplementation, we were unable to detect the ~65 kDa band. The ~23 
kDa lipoylated protein observed in the wild type lipoylation profile was no longer 
detectable after deletion of the H subunit of the GCS complex, in the presence or 
absence of lipoate supplementation. In the absence of exogenous lipoate, the 
ΔgcvH mutant has no detectable lipoylated proteins. After supplementation with 
lipoate, protein lipoylation was restored to a ΔgcvH mutant, with the exception of 
the ~23 kDa protein band. These results indicate that the ~72 kDa lipoylated 
protein corresponds to E2-PDH, the ~65 kDa molecular weight species to E2-
OGDH, and the ~23 kDa protein to the H subunit of the GCS. By process of 
elimination, E2-BCODH corresponds to the 51 kDa lipoylated protein band 
(Figure 5B). The defects in global protein lipoylation observed for the ΔgcvH 
mutant in the absence of lipoate suggests that de novo biosynthesis of lipoate 
and subsequent protein transfer in S. aureus occurs sequentially, with GcvH 






Figure 5: Identification of lipoylated proteins in wild type S. aureus 
Total cell lysates were obtained from wild type S. aureus or the indicated mutant strains grown 
until early stationary phase (9 h). Protein lysates were resolved by SDS-PAGE and detected with 
anti-lipoic acid antibody. A. Immunoblot of wild type S. aureus and mutant strains in the absence 
(BCFA) or presence of lipoate supplementation (BCFA-LA). B. Identity of each lipoylated protein 
















The role of S. aureus putative gene products involved in de novo 
biosynthesis of lipoate 
  Assessing the ability to replicate and lipoylate proteins in the presence or 
absence of lipoate/octanoate is a useful tool that allows us to identify gene 
products with roles in de novo biosynthesis versus lipoate salvage. Any lipoate 
biosynthesis mutant whose gene product plays a strict role in de novo 
biosynthesis will be rendered auxotrophic for lipoate. To test the roles of lipA, 
lipL, lipM, lplA1, and lplA2 in de novo biosynthesis and salvage we generated the 
following deletion mutant strains: ΔlipA, ΔlipA + lipA, ΔlipM, ΔlipM + lipM, ΔlipL, 
ΔlipL+pta lipL (referred in figure 6 as ΔlipL+ lipL), ΔlplA1, ΔlplA2.  
The mutant strains were studied using two straightforward assays, (i) 
assessment of bacterial growth and (ii) protein lipoylation in the presence or 
absence of lipoate and octanoate. Interestingly, supplementation of 25 nM lipoate 
was sufficient to stimulate growth, but 5 µM lipoate was needed to detect lipoate 
in the immunoblot. In contrast, higher concentrations of lipoate (250 µM) were 
required to promote growth in vitro, while lipoylated proteins after octanoate 
supplementation could be detected using 175 µM of octanoate. The high 
concentrations of octanoate required for cell replication in our studies were 
consistent to what has been found in E. coli, for which it has been shown a 
decreased rate of octanoate uptake compared to lipoate uptake (69). 
As expected, the lipoate auxotroph ΔlipA mutant was not able to grow in 
the absence of lipoate. (Figure 6A), nor was it able to replicate after octanoate 
supplementation (Figure 6C), but it could replicate when lipoate was 
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supplemented in the medium (Figure 6B), confirming a role in de novo 
biosynthesis of lipoate. Immunoblots revealed that ΔlipA is unable to lipoylate the 
target proteins when grown in medium that lacks free lipoate (Figure 6A), noted 
by the absence of the 4 bands corresponding to lipoylated E2 and H subunits 
found in wild type. In contrast, we detect wild-type lipoylation levels after lipoate 
supplementation, but not after octanoate supplementation (Figure 6B and C). 
These results, along with the successful complementation in ΔlipA + lipA, 
supports a role for LipA as a lipoate synthetase, which converts the octanoyl 
group to lipoate in GcvH.  
 A ΔlipM mutant was unable to replicate in RPMI (Figure 6A) without lipoate or 
octanoate supplementation. This indicates that the lipM gene product is involved in de 
novo biosynthesis despite its annotation as a salvage enzyme. Restoration of ΔlipM 
replication was achieved by supplementing either lipoate or octanoate (Figure 6B and C). 
Similar to ΔlipA, we detected no lipoylated proteins for ΔlipM in the absence of 
exogenous lipoate (Figure 6A). Lipoylation occurred in the presence of lipoate (Figure 
6B), presumably because the salvage function performed by the lipoate ligases 
remained intact. In addition, lipoylation was also restored after octanoate 
supplementation, indicating that LipM is capable of ligating octanoate to the target 
proteins, which is then irreversible converted to lipoate by the action of LipA (Figure 6C). 
Complementation with lipM further supported the role of the lipM gene product as an 
octanoyl transferase. Thus, our results suggest that the lipM gene product is involved in 
promoting lipoate biosynthesis from an octanoate precursor in the step that precedes  




Figure 6: Identification of de novo biosynthesis enzymes 
LipA and LipM are required for de novo biosynthesis of lipoate. Growth curves (left) and 
immunoblots using anti-lipoic acid antibody (right) of whole cell lysates of strains grown in 
RPMI+BCFA (A), RPMI+BCFA+Lipoate (B), RPMI+BCFA+Octanoate (C). All strains were able to 
replicate in RPMI+BCFA (Fig. 18 A- Appendix II). Coomassie Blue stained protein patterns are 




































































































































































































































































































 We were concerned about the low level of detection of the modified E2-
BCODH subunit as well as a growth delay observed when assessing a lipM 
mutant in RPMI + Octanoate (Figure 6C). We hypothesized that these defects in 
lipoylation and replication were caused by a decreased efficiency to incorporate 
octanoate through the salvage pathway, as opposed to an inability to transfer an 
octanoyl group to BCODH. To test this hypothesis, we repeated immunoblots but 
loaded 1.5X the amount of sample, after which we confirmed the presence the 
E2-BCODH subunit in the immunoblots (Figure 19). To address the delay in 
replication, we titrated the concentration of octanoate in growth curves and 
detected normal cell replication after increasing its concentration to 310 µM (data 
not shown), suggesting that inefficient use of octanoate caused the lipoylation 
defect and reduced growth rate linked to BCODH function in lipM mutants. 
 The deletion mutant ΔlipL was unable to grow regardless of lipoate and 
octanoate supplementation (Figure 6B and C), which suggests that it is not 
directly involved in lipoate salvage or lipoate biosynthesis; rather, it appears to be 
essential for aerobic growth in some capacity. To rule out the possibility of a 
switch in bacterial metabolism we tested aerobic and anaerobic growth for ΔlipA 
and ΔlipL on tryptic soy agar (TSA) plates (data not shown). While ΔlipA was 
able to replicate in both aerobic and anaerobic conditions, ΔlipL was only able to 
grow in anaerobic conditions. This supports the hypothesis that lipL gene product 
is an essential component for S. aureus aerobic growth. In addition, ΔlipL 
displayed only partial lipoylation regardless of lipoate or octanoate 
supplementation (Figure 6A-C). Lipoylated proteins corresponding to E2- OGDH 
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and GcvH were detected before and after lipoate supplementation. In contrast, 
the E2-PDH and E2-BCODH lipoylated proteins were absent. These findings 
lead us to conclude that the lipL gene product is likely not involved in de novo 
biosynthesis or in lipoate salvage per se, yet its presence is required for survival 
in vitro and efficient lipoylation of at least two of the five E2 subunits. The fact 
that the E2-PDH and E2-BCODH bands are missing in the lipoylated protein 
profile for all conditions tested indicates that lipL encodes a protein responsible 
for transferring lipoate groups to those two proteins. We can presume that the 
lack of lipoylation in E2-PDH and E2-BCODH is probably causing the replication 
arrest observed in our growth curves. Lastly, we can infer from Figure 6 that 
protein lipoylation might be occurring in sequential steps, which would coincide 
with what has been described in the literature for B. subtilis (16, 54, 61).  
 Construction of the complementation strain for ΔlipL was more 
complicated than expected. We were unable to restore growth or protein 
lipoylation after introduction of pJC1111-lipL. After examining the genetic 
organization of lipL, we noticed that this gene is located in what appears to be a 
two-gene operon along with pta (SAUSA300-0570), the gene coding for the 
phosphate acetyl transferase (Pta) (Figure 3). Pta is the enzyme responsible for 
the synthesis of acetyl phosphate from acetyl-CoA and phosphate and, along 
with the enzyme acetyl kinase (AckA), is required for S. aureus survival during 
overflow metabolism (70). Because of this genetic arrangement, we decided to 
test the hypothesis that the entire pta-lipL operon is required for full 
complementation of a ΔlipL mutant. Indeed, we were able to successfully 
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complement a ΔlipL mutant after transduction of the integrative plasmid 
pJC1111-pta-lipL (Figure 7). Further investigation of the interplay between Pta 
and LipL will help us elucidate potential connections between metabolic output 
and protein lipoylation or novel regulatory schemes associated with protein 
lipoylation that may dictate shifts in metabolic flux. 
 Lastly, the putative lipoate ligase deletion mutants, ΔlplA1 and ΔlplA2, 
were able to replicate and to lipoylate proteins in all three conditions tested 
(Figure 6A-C), which suggests that these enzymes are not involved in de novo 
biosynthesis, and may play a role in lipoate/octanoate salvage. However, we 
cannot yet assign a lipoate ligase function to these two genes until we test them 
in a genetic background that cannot use de novo biosynthesis to generate 
lipoate. 
 
Figure 7: Complementation of ΔlipL 
ΔlipL growth and lipoylation defects are restored after complementation with the pta-lipL operon. 
Growth curves (left) in RPMI and immunoblots with anti-lipoic acid antibody (right) from whole cell 







The requirement of lipoate de novo biosynthesis in vivo 
 Our results have revealed that S. aureus requires the lipoate salvage 
pathway to replicate in vitro when de novo biosynthesis is not functional. To test 
whether or not de novo biosynthesis of lipoate is required for survival of S. 
aureus in vivo, we assessed the ability of a ΔlipA mutant to colonize and infect 
mice using murine sepsis model. Six to eight week old female Swiss Webster 
mice were infected by retro-orbital venous plexus injection with ~1x107 colony 
forming units (CFU)/mL of WT, ΔlipA and ΔlipA + lipA and infection was allowed 
to proceed for 96 hours. We suspected that if de novo biosynthesis of lipoate 
were promoting S. aureus survival in vivo, then we should detect a decreased 
bacterial burden in infected organs. In contrast, if de novo of lipoate were 
dispensable, we should observe equivalent pathogenesis to that of wild type. 
 In the kidney, we detected no significant changes in bacterial burden 
between the wild type strain, ΔlipA or ΔlipA-lipA (Figure 8). However, in the heart, 
we observed a drastic decline in the ability of ΔlipA to colonize, with a 3-log 
reduction in bacterial CFU and a significant number of mice (N=8) having no 
recoverable bacteria. We also evaluated S. aureus seeding in liver and spleen of 
mice after systemic infection. Regrettably, no CFU for WT and other strains were 
detected in these tissues at 96 hours post infection.  
 From these results, we can conclude that de novo biosynthesis of lipoate 
is required to colonize the heart of mice in a systemic model of infection. Based 
on our previous results, we hypothesize that the efficient infection in the kidneys 
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relies upon the enzymatic activity of the lipoate ligases to maintain infectivity. 
Thus, when the ability to synthesize lipoate is blocked, S. aureus can satisfy the 
requirement for lipoate by scavenging this cofactor from the kidney environment. 
To fully assess the validity of this assumption, we will need to identify the lipoate 













Figure 8: Requirement for lipoate de novo biosynthesis in vivo 
De novo biosynthesis of lipoate is required for infection of the heart but not the kidney during 
sepsis. Bacterial burden displayed as log10CFU in kidneys and heart at 96 hours post 
bloodstream infection with 1.0 x 107 CFU of WT (N=8), ΔlipA (N=19) and ΔlipA + lipA (N=8). 
Median expressed as a measure of central tendency. In the heart, only one mouse had no 
recoverable bacteria, compared to 8 mice with undetectable CFU in the lipA deletion mutant. 
Statistics were calculated via nonparametric 1-way ANOVA and statistical significance in CFU 
values was evaluated using Krustal-Wallis multiple group comparisons. Evaluation of the results 
found in the heart between WT and ΔlipA showed a P<0.05 (*). Statistical significant differences 
where found in ΔlipA compared to ΔlipA + lipA had P<0.001 (**).  
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Characterization of the lipoate ligases constructed in a ΔlipA 
background 
To evaluate the lipoate salvage function in isolation, we generated ligase 
mutants in a ΔlipA mutant background of S. aureus. This blocks the synthesis of 
lipoate de novo and permit assessment of ligase activity. The following mutants 
were constructed: ΔlipA ΔlplA1, ΔlipA ΔlplA2 and their complemented strains 
ΔlipA ΔlplA1+lplA1, ΔlipA ΔlplA2+lplA2. Additionally, we generated ΔlplA1 
ΔlplA2, which lacks both putative lipoate ligase genes, but is still capable of 
engaging in de novo biosynthesis of lipoate. With these mutants, if the genes 
encoding putative lipoate ligases are involved in lipoate salvage, then they 
should no longer replicate and lipoylate when supplemented with lipoate.  
 As expected, the double ligase mutant ΔlplA1 ΔlplA2 replicates and 
lipoylates proteins in all three conditions tested (Figure 9). In contrast, ΔlipA 
ΔlplA1 and ΔlipA ΔlplA2 were unable to replicate and lipoylate proteins in RPMI 
lacking lipoate or octanoate (Figure 9A and C). When supplemented with lipoate 
(Figure 9B), a ΔlipA ΔlplA2 replicates normally and exhibits WT lipoylation 
profiles. Thus, lipoate salvage in vitro appears to depend on LplA1. Strikingly, 
when we tested the ΔlipA ΔlplA1 strain, we saw no restoration of growth and the 
ability to lipoylate proteins was lost, implying LplA1 is the primary lipoate ligase in 
vitro. Importantly, complementation of ΔlipA ΔlplA1 with their corresponding 
genes fully restored wild type growth phenotypes and lipoylation profiles after 




Figure 9: Assessment of lipoate ligases in the background of ΔlipA 
LplA1 behaves as a lipoate ligase in vitro. Growth curves (left) and immunoblots detected with 
anti-lipoic acid antibody (right) of whole cell lysates of strains grown in RPMI+BCFA (A), 
RPMI+BCFA+Lipoate (B), RPMI+BCFA+Octanoate (C). All strains were able to replicate in 
RPMI+BCFA (Fig. 18 B- Appendix II). Coomassie Blue stained protein patterns are shown in 




































































































































































 These results suggest that the two putative lipoate ligases, LplA1 and 
LplA2 do not behave similarly in vitro, with only LplA1 playing a role in lipoate 
salvage under these conditions. Nevertheless, it is possible that we are not 
detecting LplA2 activity with the methods used in this study. Alternatively, lplA2 
might not be expressed in broth culture. Studies evaluating LplA2 preferred 
lipoylated substrates and target proteins as well as lplA2 expression would be 
necessary to fully understand the behavior of LplA2 in vitro. 
Evaluation of the lipoate salvage pathway in a triple deletion 
mutant strain  
 Our results with ligase mutants constructed in a lipA deletion background 
showed that LplA2 was not engaging in lipoate ligation in vitro. This contrasted 
with the observations in L. monocytogenes, in which both of the lipoate ligases 
are capable of using lipoate in vitro, albeit with different affinities (61). 
 Additionally, the literature indicates that LplA2 is encoded in an operon 
that is upregulated under oxidative stress conditions (52, 53), so it is plausible 
that this gene is not sufficiently expressed under our experimental conditions. To 
test whether the constitutive expression of LplA2 renders protein lipoylation and 
allows replication in vitro, we generated the ΔlipA ΔlplA1 ΔlplA2 mutant strain 
and we individually complemented this strain with lplA1 and lplA2. If LplA2 has 
the ability to ligate lipoate in vitro, then we should observe restoration of wild type 




Figure 10: Assessment of lipoate ligases in triple deletion mutants 
LplA2 facilitates lipoylation of E2 subunits and GcvH in vitro when constitutively expressed. 
Growth curves (left) and immunoblots detected with anti-lipoic acid antibody (right) of whole cell 
lysates of strains grown in RPMI+BCFA (A), RPMI+BCFA+Lipoate (B), RPMI+BCFA+Octanoate 
(C). All strains were able to replicate in RPMI+BCFA (Fig. 18 D- Appendix II). Coomassie Blue 
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 As expected, ΔlipA ΔlplA1 ΔlplA2 was incapable of replication and protein 
lipoylation in the absence and presence of supplements (Figure 10). In contrast, 
ΔlplA1 ΔlplA2 replicates and lipoylates proteins at wild type S. aureus levels in all 
three conditions tested. The supplementation of lipoate in a triple mutant 
complemented with lplA1 also restored protein lipoylation and growth to wild type 
levels. Interestingly, complementation with lplA2 led to partial protein lipoylation 
and no restoration of growth. These results suggest that LplA2 is capable of 
ligating lipoate in vitro when constitutively expressed albeit at levels that are 
insufficient to restore growth. 
The contribution of lipoate ligases to lipoate salvage in a lipM 
deletion background 
We constructed strains in a ΔlipM mutant background to determine 
whether the lipoate ligases LplA1 and LplA2 play a role in salvage of lipoate or 
octanoate during the initial steps of lipoate de novo biosynthesis. A ΔlipM single 
deletion mutant behaved as previously described (Figure 6), while a ΔlipA ΔlipM 
double mutant was incapable of lipoylating proteins or replicating in all conditions 
tested due to the blockade of the lipoate de novo biosynthesis pathway (Figure 
11). As anticipated, ΔlipM ΔlplA1 and ΔlipM ΔlplA2 mimicked the results 
observed for the lipoate ligases in the background of a ΔlipA when media was 
supplemented with lipoate (Figure 9B and Figure 10B). LplA2 function, as 
assessed via ΔlipM ΔlplA1, showed no role for salvage of octanoate. In contrast, 
the growth phenotype and lipoylation profile of ΔlipM ΔlplA2 revealed that LplA1 




Figure 11: Assessment of lipoate ligases in the background of ΔlipM  
LplA2 is capable of ligating octanoate through the salvage pathway. Growth curves (left) and 
immunoblots detected with anti-lipoic acid antibody (right) of whole cell lysates of strains grown in 
RPMI+BCFA (A), RPMI+BCFA+Lipoate (B), RPMI+BCFA+Octanoate (C). All strains were able to 
replicate in RPMI+BCFA (Fig. 18 C- Appendix II). Coomassie Blue stained protein patterns are 







































































































































































This information was confirmed by the ΔlipM ΔlplA1+lplA1 strain, for which 
we observed restoration of a ΔlipM mutant protein lipoylation and growth 
phenotype. Taken together, these data suggest that LplA1 can provide 
octanoylated proteins to LipA, independently of the enzymatic activity of LipM.  
Assessment of the requirement for lipoate salvage in vivo 
We have demonstrated that biosynthesis of lipoate is required for heart 
infection in mice during sepsis. In contrast, the enzymatic function of LipA was 
dispensable for kidney infection. Therefore, we tested the hypothesis that the 
salvage of lipoate supports efficient infection in the renal tissue. Additionally, we 
tested whether or not LplA2 play a role in lipoate salvage during infection.  
We infected mice with either the single deletion mutants of the lipoate ligases; 
with the ΔlplA1 ΔlplA2 double mutant or with the complemented strains ΔlplA1 
ΔlplA2 + lplA1 and ΔlplA1 ΔlplA2 + lplA2. Our results show that in the kidneys, 
ΔlplA1 and ΔlplA2 had bacterial burden levels equivalent to those detected in 
both the wild type strain and the lipA deletion mutant, indicating that neither 
LplA1 nor LplA2 are essential to colonize this tissue (Figure 12). Remarkably, 
kidney infection with a ΔlplA1 ΔlplA2 double mutant was severely compromised 
in the host, showing a 4-log reduction in bacterial burden compared to the wild 
type strain. This suggests that both lipoate ligases are required for efficient 
infection of the renal tissue. Interestingly, bacterial seeding after infection with 
ΔlplA1 ΔlplA2 was not completely eliminated, supporting the notion that lipoate 





Figure 12: Assessment of the requirement for lipoate salvage in vitro 
Lipoate ligases LplA1 and LplA2 are individually required for efficient infection of the kidney. 
Bacterial burden displayed as log10CFU in kidneys and heart at 96 hours post bloodstream 
infection with 1.0 x 107 CFU of WT (N=20), ΔlipA (N=15), ΔlipA1 (N=15), ΔlipA2 (N=14), 
ΔlipA1ΔlipA2 (N=16), ΔlipA1ΔlipA2 + lplA1 (N=12) and ΔlipA1ΔlipA2 + lplA2 (N=12). Median is 
expressed as a measure of central tendency. Statistics were calculated via nonparametric 1-way 
ANOVA and statistical significance was evaluated using Krustal-Wallis multiple group 
comparisons. Analysis of the statistical significant differences in CFU showed P<0.0001 for 














































































































































ΔlipA1 and ΔlipA1ΔlipA2 + lplA2 (*). In the heart, a P<0.05 value of statistical difference was 
observed for WT compared to ΔlipA. 
 
Additionally, bacterial burden levels for ΔlplA1 ΔlplA2 + lplA1 or ΔlplA1 ΔlplA2 + 
lplA2 were near those found for the wild type strain. Taken together, these data 
suggest that both lipoate ligases can compensate for one another to facilitate 
infection of the kidneys (Figure 12). 
 The results for heart infection revealed that bacterial infection in this tissue 
is dependent on the de novo biosynthesis of lipoate. When we infected mice with 
ΔlplA1, ΔlplA2, or with ΔlplA1 ΔlplA2, no significant alterations in bacterial burden 
were detected. This indicates that lipoylation through the salvage pathway does 
not contribute significantly to pathogenesis of the heart (Figure 12).  
 In sum, we can conclude that de novo lipoate biosynthesis is essential for 
S. aureus survival in the heart during sepsis. Additionally, S. aureus 
pathogenesis in the kidneys relies upon the lipoate salvage pathway, a process 
that is supported by both lipoate ligases LplA1 and LplA2. 
Evaluation of the role of the lipoyl transferase LipL in de novo 
biosynthesis and salvage of lipoate  
 Our previous experiments showed that LipL transfers lipoyl groups to E2-
PDH and E2-BCODH; nevertheless, our assessments were insufficient to define 
which enzyme is responsible for the lipoylation of E2-OGDH and GcvH. To gain 
knowledge on this matter, we generated a set of mutant strains constructed in a 
ΔlipL background and performed immunoblots of ΔlipA ΔlipL; ΔlipM ΔlipL; ΔlipL 
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ΔlplA1; ΔlipL ΔlplA2; and ΔlipL ΔlipA ΔlipM. We did not execute growth curves in 
RPMI supplemented with lipoate or octanoate for this mutant strains due to the 
known replication phenotype found for lipL deletion mutant (Figure 6). 
Nevertheless, cells were capable of replicating in BCFA-RPMI, as shown in 
Figure 18A, Appendix II for ΔlipL (results for the rest of the mutants described in 
this section are not shown).  
 In the absence of supplements, ΔlipA ΔlipL, ΔlipM ΔlipL and ΔlipL ΔlipA 
ΔlipM failed to lipoylate proteins (Figure 13). In the same conditions a 
ΔlipLΔlplA2 double mutant mimicked a ΔlipL single deletion mutant, indicating 
that LplA2 is not involved in lipoylating E2-OGDH or GcvH. Interestingly, this was 
not the case for ΔlipLΔlplA1, for which we detected lack of lipoylation for E2 -
OGDH. This result implies that LplA1 is capable of transferring a lipoyl group 
from GcvH to the E2-OGDH without lipoate or octanoate supplementation 
independently of LipL.  
 The supplementation of lipoate restores the ΔlipL protein lipoylation 
phenotype in all tested mutants with the exception of ΔlipLΔlplA1, for which the 
E2-OGDH lipoylated band remains absent (Figure 13B). Lipoate supplementation 
for ΔlipL ΔlipA ΔlipM also indicates that LplA1 is efficient at ligating lipoate to E2-
OGDH and GcvH, and it also reveals that this process can occur trough a 
mechanism that is independent of the enzymatic activity of LipA, LipM and LipL.  
 Furthermore, GcvH gets lipoylated in both ΔlipLΔlplA1 and ΔlipM ΔlipL 
mutant strains after octanoate supplementation, yet E2-OGDH remains 
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undetectable (Figure 13C). In contrast, lipoylation of GcvH does not occur in 
ΔlipA ΔlipM ΔlipL. These results indicate that both LplA1 and LipM can attach 
octanoate to GcvH, but also, that LplA1 is incapable of ligating octanoate onto 
E2-OGDH (Figure 13C). 
 
 
Figure 13: Lipoylation profiles of mutant strains in a ΔlipL background 
LplA2 is responsible for lipoylation of OGDH and GcvH. Growth curves (left) and immunoblots 
detected with anti-lipoic acid antibody (right) of whole cell lysates of strains grown in RPMI+BCFA 
(A), RPMI+BCFA+Lipoate (B), RPMI + BCFA + Octanoate (C). Coomassie Blue stained protein 











































































































Taken together, these data support the hypothesis that protein lipoylation 
initiates through octanoylation of GcvH, either via the enzymatic activity of LipM 
or the function of LplA1. Additionally, it implies that lipoate de novo biosynthesis 
occurs in sequential steps in S. aureus. This process initiates through lipoylation 
of GcvH and continues with the transfer of the lipoyl group to E2-PDH and E2-
BCODH via the action of LipL. In contrast, lipoylation of E2-OGDH via LplA1 
seems to occur exclusively through ligation of free lipoate.  
Evaluation of S. aureus requirement for lipoate during infection 
and the individual contribution of lipoate ligases in vivo 
 Efficient infection of the renal tissue during sepsis depends on lipoate 
scavenging. When we tested ΔlplA1 ΔlplA2 in this infection model we observed a 
significant decrease in bacterial burden compared to the wild type. Nevertheless, 
we could still detect bacterial colonization, meaning that the de novo biosynthesis 
pathway, which is functional in this mutant, was possibly enabling infection in this 
tissue. To determine whether or not S. aureus requires lipoate acquisition in any 
capacity to survive during sepsis we used a ΔlipA ΔlplA1 ΔlplA2 triple mutant that 
lacks the ability to engage in both de novo biosynthesis and salvage of lipoate. 
This mutant was completely avirulent in vivo (Figure 14), indicating that S. aureus 
requires lipoic acid in vivo and cannot switch to other metabolic pathways 
(anaerobic metabolism) to bypass this requirement. Infection with the 
complementation strains ΔlipA ΔlplA1 ΔlplA2 + lplA1 and ΔlipA ΔlplA1 ΔlplA2 + 
lplA2 confirmed our previous results; both lipoate ligases can incorporate lipoate 
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in vivo, promoting bacterial replication in the host. In sum, these results allowed 
us to validate and further characterized the de novo biosynthesis and salvage 
pathway but, more importantly, provided insight into one of the mechanisms used 











Figure 14: Assessment of the requirement for lipoate acquisition  
S. aureus requires acquisition of lipoate to infect the kidney. Either LplA1 or LplA2 suffice to 
restore infection in the renal tissue. Bacterial burden displayed as log10CFU in kidneys and heart 
at 96 hours post bloodstream infection with 1.0 x 107 CFU of WT (N=21), ΔlipAΔlipA1ΔlipA2 
(N=20), ΔlipAΔlipA1ΔlipA2 + lplA1 (N=14) and ΔlipAΔlipA1ΔlipA2 + lplA2 (N=15). Median is 
expressed as a measure of central tendency. Statistics were calculated via nonparametric 1-way 
ANOVA and statistical significance was evaluated using Krustal-Wallis multiple group 
comparisons. Analysis of the statistical significant differences in CFU showed P<0.0001 (****), 
















































 The central hypothesis of this work was that lipoate acquisition 
mechanisms are capable of promoting S. aureus infectivity. In order to 
test this hypothesis, we first needed to elucidate the mechanisms by 
which S. aureus lipoate acquisition occurs. We used bacterial genetics 
techniques to generate mutant strains containing deletions in the five 
lipoate biosynthesis and salvage genes of S. aureus. The mutants were 
later assessed for their ability to lipoylate proteins and to replicate in vivo 
and in vitro in the presence or absence of lipoic acid or octanoic acid. A 
working model for the lipoate de novo biosynthesis and salvage pathway 
in S. aureus is shown in Figure 15. 
 During the course of this work, we confirmed that S. aureus has four 
lipoylated enzyme complexes (PDH; OGDH; BCODH and GCS) that 
require a lipoate modification on one of its subunits in order to become 
active. GcvH-L is an additional protein that bears lipoate but was 
undetected under the conditions tested in our work. This protein is 




stress conditions, which could explain why we were unable to detect it in 
our immunoblots (53). Our work also determined that S. aureus uses two 
mechanisms to incorporate lipoate onto these enzyme complexes, the de 
novo biosynthesis and the salvage pathway. Additionally, we have 
characterized the gene products involved in this pathway and found 
unexpected results that might suggest a potential role of lipoate 
biosynthesis enzymes in regulation of metabolic processes in S. aureus 
and in resistance to host defenses. 
 After elucidation of the lipoate de novo biosynthesis and salvage 
pathway in S. aureus, we evaluated the roles of lipoate metabolism in vivo 
using a mouse model of sepsis. We measured the ability of mutant strains 
to colonize host tissues and we found that, during sepsis, S. aureus relies 
either on lipoate de novo biosynthesis or salvage to infect the host. This 
process occurs in a tissue-dependent manner and confirms our hypothesis 
that mechanisms of lipoate acquisition contribute to S. aureus fitness and 
pathogenesis. Importantly, we were able to confirm that lipoate 
metabolism and, by extension, aerobic metabolism, is essential for S. 
aureus pathogenicity. 
Lipoate de novo biosynthesis and salvage pathway 
LipA and LipM are lipoate de novo biosynthesis enzymes 
 As shown in Figure 6, we were able to confirm the hypothesis that LipA is 




lipoylate proteins after lipoate supplementation. LipM was identified as the 
octanoate transferase after observing restoration of growth and protein lipoylation 
to wild type levels when lipoate or octanoate were supplemented in the culture 
medium. The contribution of LipA and LipM to de novo biosynthesis of lipoate 
was further confirmed after the assessment of the double deletion mutant ΔlipA 
ΔlipM and the complemented strain ΔlipA ΔlipM + lipM, both of which could not 
be rescued by octanoate supplementation Figure 11.  
Only LplA1 is required for in vitro utilization of lipoate 
 In silico analysis predicted that S. aureus encodes two lipoate 
ligases involved in salvage of lipoate, LplA1 and LplA2. The combined 
information, provided by the deletion mutants of the lipoate ligase genes 
and the mutants constructed in the background of ΔlipA revealed that only 
LplA1 is involved lipoate scavenging in vitro. This was evident in the ΔlipA 
ΔlplA1 mutant, for which LplA2 was incapable of facilitating growth and 
protein lipoylation regardless of lipoate supplementation Figure 9.  
 Previous research has shown that S. aureus LplA2 lipoylates GcvH-
L, a glycine cleavage system H-like protein that is encoded in the same 
operon as LplA2 (53). We were not able to detect lipoylation of GcvH-L 
during the course of this thesis, probably due to reduced expression of 
this operon in vitro (52). Yet, a few additional hypotheses that are not 
mutually exclusive could explain the observed lack of observable activity 




 First, LplA2 might be less efficient at ligating free lipoate compared 
to LplA1. This was the case for differences observed between L. 
monocytogenes lipoate ligases (19, 61). Another hypothesis is that S. 
aureus LplA2 uses a different substrate in place of free lipoate, such as 
peptide-bound lipoate. This is supported by the investigations conducted 
by Rack et al., in which S. aureus LplA2 was shown to lipoylate the non-
canonical GcvH using lipoamide, a lipoic acid derivative (53). Finally, 
lplA2 may not being expressed under the conditions tested in this thesis.  
 Support for the last hypothesis comes from results observed after 
complementing back the lplA2 gene in the triple mutant ΔlipM ΔlplA1 
ΔlplA2 (Figure 12). The ΔlipM ΔlplA 1ΔlplA2 + lplA2 strain displayed partial 
lipoylation of proteins, a result most likely explained by the nature of the 
complementation construct, which expresses lplA2 constitutively. 
 Additional support for the regulation hypothesis is derived from the 
fact that lplA2 is known to be encoded in an operon that seems to be 
upregulated under oxidative stress conditions (52, 53). We could directly 
test this by generating a transcriptional reporter fusion to gfp followed by 
evaluating GFP expression under redox stress conditions. Such stress 
conditions are easily induced in vitro using oxidative stressors capable of 
promoting formation of disulfide bonds, such as H2O, the redox cycling 
drug menadione, or diamide, a compound specific for thiol oxidation (5). 




with purified macrophages and neutrophils. If the lplA2 operon is induced 
by oxidative stress, we expect GFP fluorescence to increase in the 











Figure 15: Model pathway for lipoate acquisition in S. aureus  
S. aureus synthetizes lipoate through the de novo biosynthesis pathway and 
incorporates free lipoate from the environment via the salvage pathway. We propose 
this model pathway for S. aureus based in the combination of our results and data from 
other authors (16, 53, 59, 61). In the salvage pathway, LplA1 is capable of lipoylating 
GcvH both in vivo and in vitro. In contrast, we could only determine salvage of lipoate in 
vivo for LplA2, supporting the hypothesis that lplA2 containing operon is upregulated 
during oxidative stress conditions, as stated by Rack et al (52). These authors showed 
that LplA2 is also involved in salvage of lipoate in vivo by being capable of lipoylating 
both GcvH and GcvH-L, although the latter with grater affinity. Both LplA1 and LplA2 




shown that LplA1 was capable of attaching octanoate to GcvH and lipoate to E2- 
OGDH, although we consider this to be secondary to its main role as a salvage enzyme 
involved in lipoylation of GcvH. The biological importance of these observations is 
currently under investigation in our laboratory 
LplA1 can ligate free octanoate  
 Assessing the putative lipoate ligases in the background of a ΔlipM 
mutant increased our knowledge of the contribution of these enzymes to 
the salvage of octanoate. As shown in the immunoblots and growth curves 
of ΔlipM ΔlplA2, ΔlipM ΔlplA1 and ΔlipM ΔlplA1 + lplA1 LplA1 was capable 
of ligating the lipoate precursor, octanoate, bypassing ΔlipM (Figure 11). 
Lipoate then proceeds via the lipoate synthetase LipA, which would 
convert the octanoyl group to lipoate. Whether LplA1 is capable of using 
both free and peptide-bound octanoate is unknown. In contrast to what 
was observed after the complementation of LplA2 in a ΔlipA ΔlplA2 + 
lplaA2 mutant strain, the constitutive expression of lpla2 in ΔlipM ΔlplA2 
did not restore growth or protein lipoylation, suggesting that LplA2 cannot 
catalyze octanoate ligation under our experimental conditions.  
 Interestingly, lipoate ligase-mediated octanoylation was previously 
observed for LplA1 of L. monocytogenes as well as LplJ of B. subtilis (54, 
61). This argues in favor of a lipoate ligase-dependent pathway for protein 
octanoylation that is independent of LipM. From our knowledge of the 
lipoate biosynthesis and salvage pathway in other species and our own 




LplA1 and, subsequently, LipA inserts two sulfur atoms, converting the 
octanoyl moiety to a lipoyl moiety.  
 A deep assessment of the octanoylation capacity of LplA1, as well 
as LipM is complicated due to the endogenous biosynthesis of octanoate. 
Nevertheless, octanoylation of GcvH could be tested through enzymatic 
studies in vitro or by generating a triple mutant of the lipoate ligases and 
the lipoate synthetase in the background of a fatty acids auxotroph strain. 
LipL is required for efficient protein lipoylation in S. aureus 
 Based on bioinformatics analyses and similarities to B. subtilis LipL, 
the product of the 0571 gene, LipL, is predicted to encode a lipoate 
transferase. Growth assessment of a ΔlipL mutant showed that this strain 
was incapable of replicating even after supplementation with lipoate or 
octanoate. Additionally, we observed lipoylation defects in a ΔlipL mutant, 
such that only lipoylated GcvH and E2-OGDH could be detected.  
 Replication of ΔlipL in RPMI BCFA medium was normal (Figure 18A 
Appendix II), indicating that this strain was metabolically competent and 
only the absence of functional E2-PDH and E2-BCODH was responsible 
for growth arrest. We suspect ΔlipL replication arrest could be explained 
by the lack of a functional BCODH, which causes alterations in membrane 
fluidity due to defects in short branched-chain fatty acid biosynthesis and 





 Importantly, the results observed in Figure 13 were consistent with 
the findings published on B. subtilis LipL, which showed abrogated growth 
in vitro and partial protein lipoylation in a lipL deletion mutant (59), as well 
as with the role of LipL as a lipoyl-transferase in L. monocytogenes. 
Although we do not have direct evidence of LipL transferring lipoylated 
groups to E2-OGDH, based on the role of LipL in other species we 
presume this protein is capable of attaching a lipoyl molecule to this 
subunit. We demonstrated that LplA1 is capable of lipoylating E2-OGDH 
when LipL is absent, but we suspect this is not the predominant lipoylation 
mechanism for this subunit under normal conditions. Most likely, 
lipoylation of E2-OGDH is secured via LipL. Therefore, we postulate that 
LipL is a lipoyl transferase in S. aureus and is the sole enzyme involved in 
modifying the E2 subunits of lipoylated enzyme complexes in S. aureus.  
GcvH is the first protein to be lipoylated during de novo 
biosynthesis  
 The literature argues that GcvH is the first protein to get lipoylated 
in the lipoate biosynthesis and salvage pathway (11, 61, 70). From an 
evolutionary perspective, GcvH is believed to be an ancestral protein 
bearing the first lipoyl domain that arose in nature (11). This notion is 
based on the conserved structure and role of the glycine cleavage 
complex, which catalyzes a process that is virtually essential throughout 




biosynthesis, which are known to be dispensable in many organisms (11, 
72). The hypothesis that GcvH is the first intermediate in lipoate 
acquisition mechanisms is supported by the fact that Achaea and Bacteria 
species that lack the glycine cleavage complex (GCS) can bypass the 
requirement for lipoylated enzyme complexes such as PDH, OGDH or 
BCODH, and do not encode genes involved in lipoate metabolism (11, 
72). Additionally, in eukaryotic microorganisms, such as P. falciparum and 
T. gondii, GcvH is almost always exclusively localized in the mitochondria 
and its lipoylation occurs through lipoate scavenging. This connection 
between the compartmentalization of GcvH in this endosymbiotic 
organelle and its lipoylation via salvage of lipoate is very interesting and 
supports the notion of GCS as the first lipoylated system in nature (16, 60, 
62). 
 Several lines of evidence in our work also support the notion that de 
novo biosynthesis and salvage of lipoate is initiated with GcvH. The first 
evidence comes from the immunoblots of the ΔgcvH strain grown in the 
absence or presence of lipoate. When GSC is not functional, lipoylation 
appears to be blocked for E2-PDH, E2-OGDH and E2-BCODH subunits 
but when lipoate salvage is permitted al E2 subunits get lipoylated, 
indicating that GcvH lipoylation is a requirement for de novo biosynthesis 
of lipoate. Furthermore, the ΔlipL ΔlipA strain, which lacks the lipoate 




despite having LipM and LplA1 present. The same results are seen for a 
ΔlipL ΔlipM double mutant in the absence of supplements. In this case, 
LplA1 is present, but there is no exogenous lipoate available. We only see 
lipoylation of GcvH in a ΔlipL ΔlplA1 mutant, which indicates that LipM is 
transferring octanoate from the ACP to GcvH.  
 When we supplement lipoate, we see lipoylation of GcvH in ΔlipL 
ΔlipA, ΔlipL ΔlipM and ΔlipL ΔlplA1 strains. The fact that OGDH cannot be 
lipoylated in a ΔlipL ΔlplA1 mutant under this condition supports the idea 
that LipM can only attach octanoate to GcvH, and that transfer of the 
lipoate group to the remaining 2-Oxoacid dehydrogenases cannot proceed 
when LipL is absent. The only exception to this case is direct lipoylation of 
E2 OGDH using free lipoate, which can be mediated by what appear to be 
accessory functions of LplA1. Supplementation of octanoate further 
supports the notion that de novo biosynthesis of lipoate initiates 
exclusively through GcvH. If we compare ΔlipL ΔlipM in RPMI alone and 
after octanoate supplementation we observe that LplA1 must ligate 
exogenous octanoate to GcvH because lipoyl-GcvH is detected by 
immunoblot. Additionally, a ΔlipL ΔlplA1 mutant grown under lipoate 
restriction reveals that LipM exclusively transfers endogenous octanoate 
from an acyl carrier protein to GcvH. Our findings are consistent with prior 
work demonstrating the B. subtilis octanoyl transferase LipM and E. coli 




H subunit of the glycine cleavage system (54, 55, 57). Additionally, B. 
subtilis lipoate ligase LplJ has been shown to use free octanoate for GcvH 
octanoylation (11). Furthermore, GcvH has also been shown to be the first 
protein subunit lipoylated in L. monocytogenes via LplA1 (61).  
 Thus, based on support from the literature and from our own 
findings, we propose that S. aureus LipM is using ACP-bound octanoyl 
groups to modify GcvH and that LplA1 is capable of using octanoate for 
the same purpose. Importantly, we cannot yet determine with absolute 
certainty that LipM only uses ACP-derived octanoate or whether it is 
capable of attaching free octanoate to GcvH. Purifying this enzyme and 
testing if it is capable of transferring the octanoyl group from an ACP to 
other protein subunits in the absence of exogenous sources of octanoate 
could serve to determine the precise octanoylation capacity of LipM. 
Moreover, constructing a strain deficient in the biosynthesis of octanoate 
could help us answer this question. Alternatively, expressing S. aureus 
LipM in an E. coli ΔfabA mutant could conceivably allow us to determine 
whether free octanoate can serve as a substrate for LipM in the absence 
of endogenous synthesis of octanoic acid. 
Importance of LipL in transfer of lipoyl moieties  
 Previous research revealed that LipL in both B. subtilis and L. 
monocytogenes catalyzes the transfer of lipoyl moieties from GcvH to the 




information and our results, we are inclined to consider that under normal 
conditions, LipL is the central enzyme responsible for transferring the 
lipoyl group to all E2 subunits of the 2-Oxoacid dehydrogenases (E2-PDH, 
E2-OGDH and E2-BCODH).   
 We postulate that LplA1, albeit capable of directly lipoylating E2-
OGDH using free lipoate, has no role in transfer of lipoate among enzyme 
complexes. We still need to directly test this hypothesis, but our model is 
supported by the data presented in Figure 5, which shows that a ΔgcvH 
mutant grown in the absence of supplements is incapable of lipoylation of 
E2 subunits. If the lipoate ligase LplA1 were capable of lipoate transfer, 
we should observe all three E2 bands in ΔgcvH mutant background, and 
that is not reflected in our results.  
 Of note, in vitro and in vivo research in B. subtilis asserts that LipL 
is capable of catalyzing the transfer of both octanoyl and lipoyl moieties 
from GcvH to all E2 subunits (54, 61). We cannot arrive to the same 
conclusion with the results presented in this thesis, but future research 
using purified LipL in lipoylation and octanoylation assays would provide a 
definitive assessment.  
Lipoate metabolism in regulation and pathogenesis  
 Upon assessing the organization of lipoate biosynthesis and 
salvage genes in the S. aureus genome (Figure 3), we noted that the 




conclusions could be drawn from this observation, except that the lipoate 
biosynthesis and salvage genes are genetically unlinked and may not be 
regulated in a concerted manner. From an evolutionary perspective, this 
dispersion may also imply that the biosynthesis and salvage genes could 
have been acquired through different mechanisms or at different moments 
during evolution. 
 Remarkably, two genes involved in S. aureus lipoate metabolism 
appear to have novel genetic linkages; the gene encoding the lipoate 
ligase LplA2 belongs to a large operon that contains genes involved in 
post-translational modification of protein (52, 53), and the gene for the 
lipoyl transferase LipL is located in a putative operon next to the gene that 
encodes the S. aureus phosphotransacetylase, Pta (this work). 
Information obtained from the literature and our own results suggest that 
this genetic arrangement is likely to have a direct impact in regulation of 
metabolic processes and possibly redox stress in pathogenesis in S. 
aureus (53). 
 The gene coding for LplA2 is located in a previously identified 
operon downstream gcvH-L and next to two genes that encode a 
macrodomain protein and a recently discovered sirtuin, SirTM, which has 
ADP-ribosyltransferase activity. ADP-ribosylation is a post-translational 
modification, often involved in regulation of essential metabolic processes 




central focus of their work, Rack et al.. defined for the first time the role of 
LplA2 in lipoylating GcvH-L, a non-canonical glycine cleavage system H 
protein. Furthermore, their research established that LplA2-dependent 
lipoylation is required for the subsequent ADP-ribosyl modification of 
GcvH-L (53).  
 Previous investigation showed that the entire operon was 
upregulated under conditions of oxidative stress (53). This information, 
along with the known antioxidant properties of lipoate, lead Rack et al. to 
propose that the observed crosstalk between lipoylation and ADP-
ribosylation is involved in modulating the response of microbial pathogens 
to host-induced oxidative stress (53). In their model, the up-regulation of 
GcvH-L lipoylation would serve to increase the availability of lipoate for 
anti-redox purposes. Beyond this conclusion, the requirement for 
lipoylation prior to ADP-ribosylation of GcvH-L is a central piece of 
information, since it also reveals a potential role for protein lipoylation in 
the regulation of essential metabolic processes in S. aureus.  
 The arrangement of lipL in the same operon that pta in the S. 
aureus genome could also have important implications in terms of 
potential regulation of metabolic processes. Figure 7 describes the 
different complementation strategies that we used to achieve restoration 
of protein lipoylation and growth of a ΔlipL mutant to WT levels. Strikingly, 




entire putative operon, suggesting a unique interaction between lipL and 
pta.  
 The pta gene codes for the phosphotransacetylase (Pta), the 
enzyme responsible for converting acetyl coenzyme A and phosphate into 
the phosphodonor acetyl-phosphate during nutrient-rich growth conditions. 
Acetyl-phosphate can be later used to generate ATP and acetate via Ack, 
the acetate kinase enzyme (4). Our data suggest that deletion of the LipL 
gene may be interfering with the function of Pta, which could potentially 
affect the Pta-Ack pathway leading to redirected carbon flux towards 
gluconeogenesis, with lactate and pyruvate accumulation (70, 73). 
 Sadykov et al. showed that a pta mutant had decreased intracellular 
levels of acetate and acetyl phosphate and increased levels of acetyl 
coenzyme A (70). Inactivation of a lipL pta would additionally block the 
pathway to the level of pyruvate, preventing its decarboxylation and 
generation of acetyl coenzyme A. When accumulated, this intermediate is 
redirected to glucose synthesis or to the TCA cycle (70, 73) 
 Interestingly, both acetyl coenzyme A and acetyl phosphate seem to 
be involved in regulation of metabolic processes in bacteria. In E. coli, 
acetyl coenzyme A acts as an acetyl donor to lysine residues during 
protein acetylation, and acetyl phosphate has been shown to interact with 
two-component signal transduction pathways acting as a phosphoryl 




alterations on gene expression and regulation of different cellular 
processes, such as organelle generation, biofilm formation, and cell cycle 
regulation (74-76). 
 With this in mind, our observations of a potential interaction 
between LipL and Pta suggest a possible role for lipoate in regulation of 
the Pta-AckA pathway. Control of the concentrations of acetyl coenzyme A 
and acetyl phosphate could influence expression of genes, post-
translational modifications of proteins, and regulation of several virulence 
factors, which could have a major impact on S. aureus fitness and 
pathogenesis. 
 If we consider the role of LipL as a lipoyl transferase and the 
importance of Pta in S. aureus metabolism and survival, the requirement 
for both pta and lipL genes when complementing a ΔlipL mutant is 
intriguing. We could speculate that this novel genetic arrangement might 
imply a potential role for LipL-dependent protein lipoylation in the 
regulation of essential metabolic activities, with an impact on S. aureus 
survival in diverse nutritional conditions. Further investigation designed to 
study LipL and Pta interactions are currently under investigation in our 
laboratory.  
The role of lipoate metabolism in S. aureus pathogenesis 
 Elucidation of the lipoate de novo biosynthesis and salvage pathway 




metabolism during infection. We hypothesized that, due to its critical role 
in maintaining metabolic flux, lipoate acquisition mechanisms affect S. 
aureus pathogenesis. Collectively, the data generated in this work 
supports this hypothesis and revealed that the source of lipoate during 
sepsis defines infection outcome in the host. 
 We used a mouse model of sepsis to study the requirement for 
lipoate acquisition mechanisms in vivo, and measured bacterial burden in 
tissues of mice infected with different mutant strains. The evaluation of 
the requirement for de novo biosynthesis of lipoate during sepsis showed 
that the endogenous lipoylation of proteins is required for S. aureus 
infection of the heart in mice. In contrast, S. aureus replication in the 
kidneys required the action of the lipoate ligases, but not lipoate 
biosynthesis functions (Figure 8).  
 The individual contribution of the lipoate ligases LplA1 and LplA2 to 
pathogenesis in vivo was determined by comparing the infection capacity of the 
single deletion mutant strains to ΔlplA1 ΔlplA2 double mutant complemented with 
either lplA1 or lplA2 in mice (Figure 12). This study allowed us to conclude that 
efficient seeding of S. aureus of the kidneys relies upon the activity the lipoate 
ligases. This was confirmed by the experiments conducted on ΔlipA ΔlplA1 
ΔlplA2 complemented with either lpla1 or lpla2 (Figure 14), demonstrating that 





 Our observations differ from the role reported for L. monocytogenes LplA1 
and LplA2, which exhibited a robust salvage activity in vitro. However, while L. 
monocytogenes LplA1 is dispensable for growth in medium containing lipoate, is 
required for intracellular replication and virulence (15, 19, 61). In contrast, S. 
aureus LplA2 cannot ligate lipoate in vitro under the conditions tested during this 
work, yet either lipoate ligases is sufficient to infect the host, indicating that LplA2 
is capable of lipoylating proteins in the host. A possible experiment to test the 
role of LplA2 in protein lipoylation in vivo could be done by isolating colonies from 
absences in the hearts and kidneys after infection with ΔlipA ΔlplA1 ΔlplA2 + 
lplA2, and evaluating the presence of lipoylated proteins via mass spectroscopy. 
 Remarkably, we were able to demonstrate in vitro lipoylation activity 
for LplA2 only after introduction of a complementation construct in the 
triple mutant ΔlipA ΔlplA1 ΔlplA2, in which the PHELP promoter 
constitutively drives the expression of lplA2. Although we could not detect 
a role in salvage of lipoate during broth culture, lplA2 expression was 
sufficient to promote sepsis in vivo to levels equivalent to that of LplA1, 
suggesting that this gene could be upregulated in the host. This was 
observed after comparing infectivity in mice of the single deletion mutants 
ΔlplA1 and ΔlplA1 to the double mutant ΔlplA1 ΔlplA2 followed by 
complementation with lplA1 or lplA2 (Figure 12). Another possible 
explanation for this result, besides a potential upregulation of lplA2 




increase on the availability of different lipoylated substrates preferred by 
LplA2 in vivo that were not supplied in broth culture. In other words, LplA2 
might have alternative preferred substrates, such as peptide-bound 
lipoate, instead of free lipoate. Conceivably, LplA2 could be interacting 
with a lipoamidase in vivo or have lipoamidase activity itself, which would 
facilitate the release of lipoate moieties from proteins and peptides 
available in vivo. An alternative explanation could be that LplA2 only 
functions to lipoylate GcvH-L, and, as mentioned above, the operon that 
contains the pair LplA2/GcvH-L is active in vivo and not in vitro (70, 73). 
 Regardless of the mechanism by which LplA2 is functioning in vivo, 
it is remarkable that S. aureus has the ability to use two lipoate ligases to 
scavenge this essential cofactor during infection. This is a novel feature of 
lipoate acquisition in pathogenic bacteria and most likely facilitates S. 
aureus adaptation to nutrient-limited environments during infection. 
Additionally, it is known that lipoate is a potent antioxidant compound and 
the efficient scavenging of this cofactor from tissues could constitute a 
strategy aimed to counter the oxidative stress response induced by the 
host during infection (11, 12, 16, 53). 
 Consistent with our in vitro findings, the assessment of the triple 
mutant ΔlipAΔlplA1ΔlplA2 in vivo established that S. aureus relies on 
lipoate acquisition for pathogenesis. In other words, S. aureus is 




metabolism, to infect the host. In sum, our data revealed that bacterial-
generated lipoate is required for infection in the heart, but host-derived 
lipoate is necessary to infect the kidneys.  
 The reason for the striking division of labor among enzymes 
involved in lipoate salvage is currently unknown, but not uncommon in 
nature. A few malarial parasites showed organelle-specific acquisition of 
lipoate, with lipoate biosynthesis supplying this cofactor in the apicoplast, 
and environmentally acquired lipoate used in the mitochondrion (14, 18, 
62). Additionally, the malarial parasite P. falciparum has two lipoate 
ligases, pfLplA1 and pfLplA2 that reside differentially in those organelles; 
pfLplA is located the mitochondrion, the site for lipoate de novo 
biosynthesis and the organelle in which PDH is synthetized. In contrast, 
pfLplA2 can be found in the mitochondrion as well as in the apicoplast, in 
which GcvH and BCDH are lipoylated. 
 Finally, differences in lipoate concentration or lipoate sources 
between the heart and the kidney could potentially explain these 
observations. In fact, Akiba et al. showed that albeit the levels of free 
lipoate are generally low in all mammal tissues the kidneys had the 
highest content of total lipoate compared to other tissues (49). 
Unfortunately, we lack more precise information on lipoylated substrate 
availability in mammalian tissues in order to draw firm conclusions on 




aureus to incorporate protein/peptide-bound lipoate from infectious 
sources. Future directions aimed at shedding light on these remaining 
problems, include: (1) Characterize the preferred sources of lipoate used 
by the enzymes involved in lipoate de novo biosynthesis and salvage; (2) 
conduct enzymatic assays to determine the affinity for different lipoylated 
substrates and; (3) evaluate the expression of the enzymes involved in 
lipoate acquisition both in vitro and in vivo. Together, these future studies 
will clarify the mechanisms used by S. aureus to promote optimal 
replication in the host and might help identify potential drug targets to fight 
S. aureus infections. 
Final remarks 
 In this thesis, we have proposed a model for the de novo 
biosynthesis and salvage pathway of lipoate in Staphylococcus aureus 
and demonstrated the critical role of lipoate acquisition in S. aureus 
pathogenesis. Furthermore, we have identified a previously overlooked 
genetic arrangement of lipoate de novo biosynthesis and salvage genes in 
the S. aureus genome that suggests a potential role for protein lipoylation 
in the regulation of key metabolic processes and defense mechanisms 
against host oxidative burst. We have also established the biological 
function of each gene product involved in lipoate metabolism and 
determined the contribution of the lipoate acquisition mechanisms to S. 




utilizing bacterial and host-derived lipoate during infection in a tissue-
specific manner, thereby promoting survival in a wide variety of nutrient-
restricted environments. The significant defects in virulence seen after 
blocking de novo biosynthesis and salvage of lipoic acid during sepsis 
offer potential for the development of novel therapeutics that target lipoate 












PERMISSION TO REPRODUCE COPYRIGHTED CONTENT 


















































Figure 17: Growth curves of mutant sets in RPMI BCFA 
Growth curves in RPMI BCFA of the indicated mutant strains sets: A) Single deletion mutants 
(ref. Fig. 5), B) Double deletion strains constructed in the background of a lipA deletion mutant 
(ref. Fig. 8), C) Double deletion strains constructed in the background of a lipM deletion mutant 
(ref. Fig. 10) D), Triple deletion strains of the de novo biosynthesis and salvage pathway enzymes 













Figure 18: LipM lipoylation profile  
LipM is capable of protein lipoylation to E2-OGDH. Immunoblots of whole cell lysates of the 
indicated mutant strains grown in RPMI + BCFA + Octanoate, detected with anti-lipoic acid 
antibody (C). This experiment was performed as previously described but the amount of sample 






Figure 19: Whole cell protein patterns I 
Proteins from whole cell lysates were resolved in 12% polyacrylamide gels and stained using 
GelCode Blue stain reagent (Thermo). The molecular weight of the proteins was marked using 
Precision Plus Protein Ladder™ (Thermo). The rows organize samples grown in 
RPMI+BCFA media (BCFA), RPMI+lipoate (+LA) or RPMI+octanoate (+OA). Columns 
organize the set of mutants tested: the first column depicts the protein patterns of the set 
of mutants used in figure 6. The column at the center reflects the protein patterns of 
mutants used for figure 9. Protein patterns of mutant strains tested in figure 11 are 















































































































Figure 20: Whole cell protein patterns II 
Proteins from whole cell lysates were resolved in 12% polyacrylamide gels and stained using 
GelCode Blue stain reagent (Thermo). The molecular weight of the proteins was marked using 
Precision Plus Protein Ladder™ (Thermo). The rows organize samples grown in 
RPMI+BCFA media (BCFA), RPMI+lipoate (+LA) or RPMI+octanoate (+OA). The right 
column depicts the protein patterns of the set of mutants used in figure 13. The protein 
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